571.4 2. Molecular basis of transient outward potassium current downregulation in human h Circulation 98: 1383-93. (1998).

317.2 3. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-23. (2005).

200.0 4. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. Circ Res 80: 261-8. (1997).

166.7 5. In vivo identification of genes that modify ether-a-go-go-related gene activity Proc Natl Acad Sci U S A 101: 11773-8. (2004).

149 6. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie 55: 195-202. (0).

115 7. Electrical alternans and hemodynamics in the anesthetized guinea pig can discrim J Pharmacol Toxicol Methods 55: 78-85. (0).

113 8. KvLQT1 modulates the distribution and biophysical properties of HERG. A novel al J Biol Chem 279: 1233-41. (2004).

106 9. Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: FASEB J 14: 2601-10. (2000).

105.6 10. HERG K+ channel expression-related chemosensitivity in cancer cells and its modu Cancer Chemother Pharmacol 56: 212-20. (2005).

105 11. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG ru Assay Drug Dev Technol 3: 47-57. (2005).

102 12. Development of the predictor HERG fluorescence polarization assay using a membrane protein Assay Drug Dev Technol 6: 213-23. (2008).

102 13. [Correlation of HERG K+ channel protein expression to chemosensitivity of tumor Ai Zheng 24: 924-9. (2005).

100 14. Automated electrophysiology in the preclinical evaluation of drugs for potential J Pharmacol Toxicol Methods 52: 123-35. (0).

100 15. The Potent Inhibitory Effects of Cisapride, a Specific Blocker for Human Ether-a Cancer Biol Ther 4: 295-301. (2005).

100 16. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ J Pharmacol Sci 95: 311-9. (2004).

100 17. Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284: H256-67. (2003).

100.0 18. Development and evaluation of high throughput functional assay methods for HERG J Biomol Screen 6: 325-31. (2001).

100.0 19. Optimisation and validation of a medium-throughput electrophysiology-based hERG J Pharmacol Toxicol Methods 0: . (2006).

100 20. A QSAR model of HERG binding using a large, diverse, and internally consistent t Chem Biol Drug Des 67: 284-96. (2006).

100 21. Design, synthesis, structure-activity relationship, and in vivo activity of azab Bioorg Med Chem 0: . (2006).

100 22. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with redu J Pharmacol Toxicol Methods 54: 130-40. (0).

100 23. Estimation of hERG inhibition of drug candidates using multivariate property and Bioorg Med Chem 0: . (2007).

100 24. Action potential experiments complete hERG assay and QT-interval measurements in J Pharmacol Toxicol Methods 0: . (2007).

100 25. Expression and fuactional role of HERG1, K(+) channels in leukemic cells and leu J Huazhong Univ Sci Technolog Med Sci 27: 257-60. (2007).

100 26. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther 7: . (2007).

100 27. hERG Classification Model Based on a Combination of Support Vector Machine Metho Mol Pharm 0: . (2008).

100 28. Identification of Novel Kv1.3 Blockers Using a Fluorescent Cell-Based Ion Channe J Biomol Screen 0: . (2005).

99 29. Evaluation of a high-throughput fluorescence assay method for HERG potassium cha J Biomol Screen 10: 339-47. (2005).

99 30. Identifying modulators of hERG channel activity using the PatchXpress planar pat J Biomol Screen 10: 168-81. (2005).

99 31. A novel membrane potential-sensitive fluorescent dye improves cell-based assays J Biomol Screen 7: 79-85. (2002).

99 32. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG ri J Pharmacol Toxicol Methods 52: 136-45. (0).

97 33. Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol wi J Biol Chem 0: . (2006).

95 34. Isolation and characterization of IKr in cardiac myocytes by Cs+ permeation. Am J Physiol Heart Circ Physiol 0: . (2005).

90 35. Evaluation of the rubidium efflux assay for preclinical identification of HERG b Assay Drug Dev Technol 4: 73-82. (2006).

85 36. A high-throughput HERG potassium channel function assay: an old assay with a new Drug Dev Ind Pharm 28: 177-91. (2002).

83.3 37. Application of cryopreserved cells to HERG screening using a non-radioactive Rb+ Assay Drug Dev Technol 4: 83-8. (2006).

82 38. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non J Pharmacol Toxicol Methods 54: 116-29. (0).

79 39. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol 29: 457-65. (2007).

79 40. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carci Oncol Rep 19: 1511-6. (2008).

79 41. Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthes J Med Chem 48: 1725-8. (2005).

78 42. NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-s J Med Chem 47: 2089-96. (2004).

78 43. Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 J Med Chem 49: 6569-84. (2006).

78 44. Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Pola J Med Chem 0: . (2007).

78 45. Improved functional expression of recombinant human ether-a-go-go (hERG) K+ chan BMC Biotechnol 7: 93. (2007).

78 46. Exploring QSTR and toxicophore of hERG K(+) channel blockers using GFA and HypoG J Mol Graph Model 0: . (2007).

77 47. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofet Clin Pharmacol Ther 77: 572-82. (2005).

75 48. Early evaluation of compound QT prolongation effects: A predictive 384-well fluo J Pharmacol Toxicol Methods 0: . (2006).

75 49. Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization an Toxicol Pathol 34: 81-90. (2006).

74 50. Rb+ flux through hERG channels affects the potency of channel blocking drugs: co J Biomol Screen 9: 588-97. (2004).

73 51. Preclinical cardiac safety assessment of pharmaceutical compounds using an integ Prog Biophys Mol Biol 90: 414-43. (0).

73 52. [3H]dofetilide binding to HERG transfected membranes: a potential high throughpu Eur J Pharmacol 430: 147-8. (2001).

71.4 53. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockad J Pharmacol Toxicol Methods 50: 187-99. (0).

71 54. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol 482: 31-7. (2003).

71 55. Drugs, hERG and sudden death. Cell Calcium 35: 543-7. (2004).

70 56. QT PRODACT: Evaluation of the Potential of Compounds to Cause QT Interval Prolon J Pharmacol Sci 99: 449-57. (2005).

70 57. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 0: . (2007).

68 58. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 0: . (2006).

67 59. Synthesis of the first sulfur-35-labeled hERG radioligand. Bioorg Med Chem Lett 16: 1692-5. (2006).

67 60. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with mini Bioorg Med Chem Lett 0: . (2006).

67 61. HERG channel trafficking. Novartis Found Symp 266: 57-69; discussi. (2005).

65 62. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molec Antimicrob Agents Chemother 49: 4721-32. (2005).

64 63. Understanding hERG inhibition with QSAR models based on a one-dimensional molecu J Comput Aided Mol Des 0: . (2007).

64 64. Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol 207: 446-50. (2005).

63 65. Mapping the receptor site for ergtoxin, a specific blocker of ERG channels. FEBS Lett 510: 45-9. (2002).

59 66. 1,4-Dihydroindeno[1,2-c]pyrazoles with Acetylenic Side Chains as Novel and Poten J Med Chem 0: . (2007).

58 67. Involvement of Golgin-160 in Cell Surface Transport of Renal ROMK Channel: Co-ex Cell Physiol Biochem 17: 1-12. (2006).

57 68. Combined hERG channel inhibition and disruption of trafficking in drug-induced l Br J Pharmacol 0: . (2006).

54 69. Cardiac Glycosides as Novel Inhibitors of HERG Channel Trafficking. J Pharmacol Exp Ther 0: . (2006).

54 70. Doxazosin induces apoptosis of cells expressing hERG K(+) channels. Eur J Pharmacol 0: . (2007).

51 71. Erg K+ channels modulate contractile activity in the bovine epididymal duct. Am J Physiol Regul Integr Comp Physiol 0: . (2008).

48 72. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35: 1060-3. (2007).

47 73. Long-QT syndrome-associated missense mutations in the pore helix of the HERG pot Circulation 104: 1071-5. (2001).

46.7 74. Acute administration of alcohol modulates pyroglutamyl amino peptidase II activi Neurochem Int 46: 347-56. (2005).

45 75. Electrophysiological effects of brompheniramine on cardiac ion channels and acti Pharmacol Res 0: . (2006).

44 76. Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol 0: . (2007).

37 77. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in th Am J Med Genet 98: 348-52. (2001).

33.3 78. QT interval prolongation: and the beat goes on. Mini Rev Med Chem 5: 1083-91. (2005).

26 79. The utility of hERG and repolarization assays in evaluating delayed cardiac repo J Cardiovasc Pharmacol 43: 369-79. (2004).

25.0 80. Analysis of the human KCNH2(HERG) gene: identification and characterization of a Hum Mutat 15: 483. (2000).

22.7
]]> http://neurobiosis.wordpress.com/2008/06/10/herg-assay-publications/feed/ 0 ssamrat http://neurobiosis.wordpress.com/2008/06/10/herg-related-publications/ http://neurobiosis.wordpress.com/2008/06/10/herg-related-publications/#comments Tue, 10 Jun 2008 05:53:28 +0000 Samrat Roy http://neurobiosis.wordpress.com/?p=32 ]]>

	Citation Score
1. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-33. (2000).	894.4
2. Relationships between preclinical cardiac electrophysiology, clinical QT interva Cardiovasc Res 58: 32-45. (2003).	571.4
3. Allelic variants in long-QT disease genes in patients with drug-associated torsa Circulation 105: 1943-8. (2002).	558.3
4. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269: 92-5. (1995).	532.7
5. The sudden infant death syndrome gene: does it exist? Pediatrics 114: e506-12. (2004).	500.0
6. Crystal structure and functional analysis of the HERG potassium channel N termin Cell 95: 649-55. (1998).	469
7. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-6. (1996).	466.7
8. Influence of genotype on the clinical course of the long-QT syndrome. Internatio N Engl J Med 339: 960-5. (1998).	466
9. A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 403: 196-9. (2000).	465.2
10. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109: 30-5. (2004).	425.0
11. Properties of HERG channels stably expressed in HEK 293 cells studied at physiol Biophys J 74: 230-41. (1998).	412.1
12. Sodium channel block with mexiletine is effective in reducing dispersion of repo Circulation 96: 2038-47. (1997).	373.5
13. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG Cell 81: 299-307. (1995).	369
14. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795-803. (1995).	365
15. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differ Circulation 92: 3381-6. (1995).	364.7
16. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A 93: 2208-12. (1996).	347.6
17. Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature 411: 805-10. (2001).	333.3
18. A minK-HERG complex regulates the cardiac potassium current I(Kr). Nature 388: 289-92. (1997).	320.6
19. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrh Cell 97: 175-87. (1999).	320
20. Molecular basis of transient outward potassium current downregulation in human h Circulation 98: 1383-93. (1998).	317.2
21. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium EMBO J 19: 6326-30. (2000).	316.7
22. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium c Nature 384: 78-80. (1996).	295
23. HERG K+ channels: friend and foe. Trends Pharmacol Sci 22: 240-6. (2001).	283.3
24. Fast inactivation causes rectification of the IKr channel. J Gen Physiol 107: 611-9. (1996).	273.9
25. Genetically defined therapy of inherited long-QT syndrome. Correction of abnorma Circulation 94: 1018-22. (1996).	267.6
26. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 73: 250-69. (1998).	266.7
27. Trapping of a methanesulfonanilide by closure of the HERG potassium channel acti J Gen Physiol 115: 229-40. (2000).	265.2
28. Correction of defective protein trafficking of a mutant HERG potassium channel i J Biol Chem 274: 31123-6. (1999).	254.2
29. hERG potassium channels and cardiac arrhythmia. Nature 440: 463-9. (2006).	250
30. Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 82: 386-95. (1998).	248.5
31. Mechanism of block and identification of the verapamil binding domain to HERG po Circ Res 84: 989-98. (1999).	246.2
32. A mutation in the C. elegans EXP-2 potassium channel that alters feeding behavio Science 286: 2501-4. (1999).	244
33. Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38: 737-44. (2001).	235.7
34. HERG, a primary human ventricular target of the nonsedating antihistamine terfen Circulation 94: 817-23. (1996).	229.4
35. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 Br J Pharmacol 139: 887-98. (2003).	220.0
36. Novel characteristics of a misprocessed mutant HERG channel linked to hereditary m J Physiol Heart Circ Physiol 279: H1748-56. (2000).	216.7
37. Blockade of HERG channels by HIV protease inhibitors. Lancet 365: 682-6. (0).	215
38. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Mol Pharmacol 57: 367-74. (2000).	213.0
39. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ Circ Res 78: 499-503. (1996).	211.9
40. Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG p J Biol Chem 274: 10113-8. (1999).	211.5
41. Position of aromatic residues in the S6 domain, not inactivation, dictates cisap Proc Natl Acad Sci U S A 99: 12461-6. (2002).	210.0
42. HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 62: 4843-8. (2002).	210.0
43. Novel mechanism associated with an inherited cardiac arrhythmia: defective prote Circulation 99: 2290-4. (1999).	207.7
44. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316-23. (2005).	200.0
45. Drug binding to aromatic residues in the HERG channel pore cavity as possible ex Naunyn Schmiedebergs Arch Pharmacol 368: 404-14. (2003).	200.0
46. The antipsychotic agent sertindole is a high affinity antagonist of the human ca J Pharmacol Exp Ther 286: 788-93. (1998).	200.0
47. High affinity open channel block by dofetilide of HERG expressed in a human cell Mol Pharmacol 49: 949-55. (1996).	200.0
48. Identification of two nervous system-specific members of the erg potassium chann J Neurosci 17: 9423-32. (1997).	194.3
49. Increased risk of arrhythmic events in long-QT syndrome with mutations in the po Circulation 105: 794-9. (2002).	192.3
50. Molecular determinants for activation and inactivation of HERG, a human inward r J Physiol 493: 635-42. (1996).	191.3
51. KCNE4 is an inhibitory subunit to the KCNQ1 channel. J Physiol 542: 119-30. (2002).	190.0
52. Instability and triangulation of the action potential predict serious proarrhyth Circulation 103: 2004-13. (2001).	188.9
53. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier p Clin Exp Pharmacol Physiol 27: 753-66. (2000).	188.9
54. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic Am J Physiol 273: H2534-8. (1997).	188.6
55. Electrophysiological characterization of an alternatively processed ERG K+ chann Circ Res 81: 719-26. (1997).	188.6
56. High throughput ion-channel pharmacology: planar-array-based voltage clamp. Assay Drug Dev Technol 1: 127-35. (2003).	187.5
57. Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr Biol 10: 671-4. (2000).	186.4
58. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related ( J Am Coll Cardiol 33: 327-32. (1999).	186.2
59. HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5- Circ Res 89: 1168-76. (2001).	178.6
60. The binding site for channel blockers that rescue misprocessed human long QT syn J Biol Chem 277: 4989-98. (2002).	176.9
61. Ethnic differences in cardiac potassium channel variants: implications for genet Mayo Clin Proc 78: 1479-87. (2003).	175.0
62. A new oral therapy for long QT syndrome: long-term oral potassium improves repol J Am Coll Cardiol 42: 1777-82. (2003).	175.0
63. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278: 2947-55. (2003).	175.0
64. Ion channel remodeling is related to intraoperative atrial effective refractory Circulation 103: 684-90. (2001).	172.2
65. The molecular genetics of the long QT syndrome: genes causing fainting and sudde Annu Rev Med 49: 263-74. (1998).	169.7
66. Inhibition of the current of heterologously expressed HERG potassium channels by Br J Pharmacol 128: 479-85. (1999).	169.6
67. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26: 119-24. (2005).	169
68. A novel mutation (T65P) in the PAS domain of the human potassium channel HERG re J Biol Chem 277: 48610-6. (2002).	166.7
69. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HE J Biol Chem 277: 23587-95. (2002).	166.7
70. Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. Circ Res 80: 261-8. (1997).	166.7
71. Pentamidine reduces hERG expression to prolong the QT interval. Br J Pharmacol 145: 15-23. (2005).	165
72. Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1. Genomics 51: 86-97. (1998).	164
73. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-relate J Pharmacol Exp Ther 300: 543-8. (2002).	161.5
74. Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and traffic Hum Mol Genet 8: 1499-507. (1999).	160.9
75. Ion channels in microglia (brain macrophages). Am J Physiol 275: C327-42. (1998).	160.7
76. APETx1, a new toxin from the sea anemone Anthopleura elegantissima, blocks volta Mol Pharmacol 64: 59-69. (2003).	160.0
77. Molecular interactions between two long-QT syndrome gene products, HERG and KCNE Circ Res 89: 33-8. (2001).	160.0
78. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid compon Circulation 102: 275-7. (2000).	159.1
79. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes J Mol Cell Cardiol 37: 1031-9. (2004).	159
80. Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of J Biol Chem 277: 18994-9000. (2002).	158.3
81. Retention in the endoplasmic reticulum as a mechanism of dominant-negative curre J Mol Cell Cardiol 32: 2327-37. (2000).	155.6
82. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are Mol Pharmacol 54: 695-703. (1998).	155.2
83. Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome. Circulation 95: 565-7. (1997).	152.8
84. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44. (2004).	150.0
85. Kv1.5 is an important component of repolarizing K+ current in canine atrial myoc Circ Res 93: 744-51. (2003).	150.0
86. Defective human Ether-à-go-go-related gene trafficking linked to an endoplasmic J Biol Chem 277: 27442-8. (2002).	150.0
87. Analysis of the cyclic nucleotide binding domain of the HERG potassium channel a J Biol Chem 276: 17244-51. (2001).	150.0
88. In vivo identification of genes that modify ether-a-go-go-related gene activity Proc Natl Acad Sci U S A 101: 11773-8. (2004).	149
89. Homozygous SCN5A mutation in long-QT syndrome with functional two-to-one atriove Circ Res 89: E16-21. (2001).	146.7
90. Structural and functional role of the extracellular s5-p linker in the HERG pota J Gen Physiol 120: 723-37. (2002).	144.4
91. KCNE5 induces time- and voltage-dependent modulation of the KCNQ1 current. Biophys J 83: 1997-2006. (2002).	144.4
92. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac po Circ Res 92: e87-100. (2003).	142.9
93. RNA interference reveals that endogenous Xenopus MinK-related peptides govern ma J Biol Chem 278: 11739-45. (2003).	142.9
94. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by Mol Pharmacol 54: 113-21. (1998).	142.9
95. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-g Circulation 105: 2830-5. (2002).	141.7
96. Regulation of HERG potassium channel activation by protein kinase C independent Cardiovasc Res 59: 14-26. (2003).	140.0
97. A comparison of the receptor binding and HERG channel affinities for a series of Eur J Pharmacol 450: 37-41. (2002).	140.0
98. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and Circ Res 78: 1009-15. (1996).	139.1
99. Computational biology in the study of cardiac ion channels and cell electrophysi Q Rev Biophys 0: 1-60. (2006).	139
100. Predictive in silico modeling for hERG channel blockers. Drug Discov Today 10: 149-55. (2005).	138
101. Sex hormones prolong the QT interval and downregulate potassium channel expressi Circulation 94: 1471-4. (1996).	138
102. Structural basis of action for a human ether-a-go-go-related gene 1 potassium ch Proc Natl Acad Sci U S A 0: . (2007).	136
103. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 286: 727-35. (1998).	135.7
104. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacr Br J Pharmacol 142: 485-94. (2004).	133.3
105. Probing the interaction between inactivation gating and Dd-sotalol block of HERG Circ Res 87: 1012-8. (2000).	133.3
106. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs w J Pharmacol Exp Ther 295: 614-20. (2000).	133.3
107. Targeted modification of atrial electrophysiology by homogeneous transmural atri Circulation 111: 264-70. (2005).	131
108. Common Genetic Variation in KCNH2 Is Associated With QT Interval Duration. The F Circulation 0: . (2007).	131
109. Sinus node function and ventricular repolarization during exercise stress test i J Am Coll Cardiol 34: 823-9. (1999).	130.4
110. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future Circulation 94: 1996-2012. (1996).	130
111. Mechanism of action of NS1643, a novel hERG channel activator. Mol Pharmacol 0: . (2005).	129
112. Cellular consequences of HERG mutations in the long QT syndrome: precursors to s Cardiovasc Res 50: 301-13. (2001).	127.8
113. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfe Proc Natl Acad Sci U S A 98: 5335-40. (2001).	127.8
114. Physicochemical features of the HERG channel drug binding site. J Biol Chem 279: 10120-7. (2004).	127
115. Disease-associated mutations in KCNE potassium channel subunits (MiRPs) reveal p FASEB J 16: 390-400. (2002).	127
116. Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127: 279-84. (2002).	126
117. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range Toxicol Appl Pharmacol 193: 370-82. (2003).	125.0
118. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQ Cardiovasc Res 60: 235-41. (2003).	125.0
119. Identification of a COOH-terminal segment involved in maturation and stability o J Biol Chem 278: 40105-12. (2003).	125.0
120. Expression of distinct ERG proteins in rat, mouse, and human heart. Relation to J Biol Chem 275: 5997-6006. (2000).	125
121. QTc prolongation by grapefruit juice and its potential pharmacological basis: HE Circulation 111: 835-8. (2005).	124
122. Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 J Biol Chem 277: 47779-85. (2002).	122
123. Atrio-sinus interaction demonstrated by blockade of the rapid delayed rectifier Circulation 105: 880-5. (2002).	122
124. Molecular mapping of a site for Cd2+-induced modification of human ether-à-go-g J Physiol 567: 737-55. (2005).	120
125. Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S a J Biol Chem 278: 35749-54. (2003).	120.0
126. Inhibition of the current of heterologously expressed HERG potassium channels by Br J Pharmacol 136: 717-29. (2002).	120.0
127. Molecular physiology and pharmacology of HERG. Single-channel currents and block Circulation 94: 2572-9. (1996).	120
128. Clinical translation of genotyping and haplotyping data : implementation of in v Clin Pharmacokinet 46: 807-24. (2007).	120
129. The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac FASEB J 17: 2263-5. (2003).	119
130. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as Pharmacol Ther 0: . (2006).	119
131. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-defic Circulation 113: 365-73. (2006).	119
132. KChAP as a chaperone for specific K(+) channels. Am J Physiol Cell Physiol 278: C931-41. (2000).	118.2
133. [Value of genetic testing in the management of the congenital long QT syndrome] Arch Mal Coeur Vaiss 96: 539-47. (2003).	117
134. 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity EMBO J 21: 1889-98. (2002).	116.7
135. Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 11: 1413-8. (2000).	116.7
136. Fast and slow voltage sensor movements in HERG potassium channels. J Gen Physiol 119: 275-93. (2002).	115.4
137. Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie 55: 195-202. (0).	115
138. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT synd J Clin Invest 0: . (2008).	115
139. Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence Circ Res 83: 415-22. (1998).	114.3
140. SPECIFIC SERINE PROTEASES SELECTIVELY DAMAGE KCNH2 (hERG1) POTASSIUM CHANNELS AN Am J Physiol Heart Circ Physiol 0: . (2005).	114
141. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 112: 1251-8. (2005).	114
142. The “final common pathway” hypothesis and inherited cardiovascular disease. The Herz 25: 75. (2000).	113.6
143. Electrical alternans and hemodynamics in the anesthetized guinea pig can discrim J Pharmacol Toxicol Methods 55: 78-85. (0).	113
144. Solution structure of CnErg1 (Ergtoxin), a HERG specific scorpion toxin. FEBS Lett 539: 138-42. (2003).	112.5
145. C-terminal domains implicated in the functional surface expression of potassium EMBO J 22: 395-403. (2003).	112.5
146. In vivo androgen treatment shortens the QT interval and increases the densities Cardiovasc Res 57: 28-36. (2003).	112.5
147. Cloning and functional characterization of the smooth muscle ether-a-go-go-relat J Biol Chem 278: 2503-14. (2003).	112.5
148. Prolonged repolarization and triggered activity induced by adenoviral expression Cardiovasc Res 61: 268-77. (2004).	112
149. Modulating effects of age and gender on the clinical course of long QT syndrome J Am Coll Cardiol 42: 103-9. (2003).	112
150. [Homozygotous mutation of the SCN5A gene responsible for congenital long QT synd Arch Mal Coeur Vaiss 95: 440-6. (2002).	112
151. C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3ep Hum Mol Genet 15: 2888-902. (2006).	112
152. New binding site on common molecular scaffold provides HERG channel specificity J Biol Chem 277: 43104-9. (2002).	111.1
153. Alterations in potassium channel gene expression in atria of patients with persi J Am Coll Cardiol 37: 926-32. (2001).	111.1
154. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49: 361-70. (2001).	111.1
155. Inhibition of IKs channels by HMR 1556. Naunyn Schmiedebergs Arch Pharmacol 362: 480-8. (2000).	111.1
156. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-relat Cardiovasc Res 48: 44-58. (2000).	111
157. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 55: 185-93. (0).	111
158. In vitro modulation of HERG channels by organochlorine solvent trichlormethane a Toxicol Lett 0: . (2006).	111
159. Time course and voltage dependence of expressed HERG current compared with nativ Pflugers Arch 436: 843-53. (1998).	110.3
160. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulat Cancer Res 64: 606-11. (2004).	110
161. Identification and functional characterization of a novel KCNE2 (MiRP1) mutation J Mol Med 80: 524-32. (2002).	110.0
162. herg encodes a K+ current highly conserved in tumors of different histogenesis: Cancer Res 58: 815-22. (1998).	110
163. HERG is protected from pharmacological blockade by constitutive alpha -1,2-gluco J Biol Chem 0: . (2006).	110
164. Heteromeric assembly of hERG 1A/1B channels occurs cotranslationally via amino-t J Biol Chem 0: . (2007).	110
165. Voltage-dependent profile of human ether-a-go-go-related gene channel block is i Mol Pharmacol 63: 1051-8. (2003).	109
166. HERG channel dysfunction in human long QT syndrome. Intracellular transport and J Biol Chem 273: 21061-6. (1998).	109
167. Atrial fibrillation-associated minK38G/S polymorphism modulates delayed rectifie Cardiovasc Res 67: 520-8. (2005).	108
168. Degradation of trafficking-defective long QT syndrome type II mutant channels by J Biol Chem 280: 19419-25. (2005).	108
169. Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-g Circulation 107: 889-95. (2003).	108
170. The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 11: 321-36. (2007).	108
171. Open channel block of HERG K(+) channels by vesnarinone. Mol Pharmacol 60: 244-53. (2001).	107
172. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents Circulation 101: 1199-205. (2000).	107
173. Overexpression of a human potassium channel suppresses cardiac hyperexcitability J Clin Invest 103: 889-96. (1999).	106.9
174. A K+ channel splice variant common in human heart lacks a C-terminal domain requ J Biol Chem 273: 27231-5. (1998).	106.9
175. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol 62: 41-9. (2001).	106.7
176. HERG-like K+ channels in microglia. J Gen Physiol 111: 781-94. (1998).	106.1
177. KvLQT1 modulates the distribution and biophysical properties of HERG. A novel al J Biol Chem 279: 1233-41. (2004).	106
178. The seizure locus encodes the Drosophila homolog of the HERG potassium channel. J Neurosci 17: 882-90. (1997).	106
179. Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: FASEB J 14: 2601-10. (2000).	105.6
180. HERG K+ channel expression-related chemosensitivity in cancer cells and its modu Cancer Chemother Pharmacol 56: 212-20. (2005).	105
181. Another dimension to calcium signaling: a look at extracellular calcium. J Cell Sci 118: 855-62. (2005).	105
182. [K(+)](o)-dependent change in conformation of the HERG1 long QT mutation N629D c Cardiovasc Res 57: 642-50. (2003).	105
183. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 23: 215-28. (2000).	104.5
184. Pathways of HERG inactivation. Am J Physiol 277: H199-210. (1999).	104.3
185. N-Glycosylation-dependent block is a novel mechanism for drug-induced cardiac ar FASEB J 17: 2308-9. (2003).	104
186. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33: 181-5. (1999).	103.4
187. Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence. J Physiol 557: 705-17. (2004).	103
188. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsad Drug Saf 25: 263-86. (2002).	103
189. New mutations in the KVLQT1 potassium channel that cause long-QT syndrome. Circulation 97: 1264-9. (1998).	103.0
190. Association of 14-3-3 Proteins to {beta}1-Adrenergic Receptors Modulates Kv11.1 Mol Biol Cell 0: . (2006).	103
191. Application of the bradford hill criteria to assess the causality of cisapride-i Drug Saf 30: 333-46. (2007).	103
192. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG ru Assay Drug Dev Technol 3: 47-57. (2005).	102
193. Automated tight seal electrophysiology for assessing the potential hERG liabilit Assay Drug Dev Technol 2: 497-506. (2004).	102
194. Development of the predictor HERG fluorescence polarization assay using a membrane protein Assay Drug Dev Technol 6: 213-23. (2008).	102
195. Different roles for K+ channels in cisplatin-resistant cell lines argue against Anticancer Res 25: 4113-22. (0).	100
196. [DNA-based diagnostics of long QT syndrome] Tidsskr Nor Laegeforen 125: 2783-6. (2005).	100
197. Inhibitory effect of rhynchophylline on human ether-a-go-go related gene channel Sheng Li Xue Bao 57: 648-652. (2005).	100
198. [Correlation of HERG K+ channel protein expression to chemosensitivity of tumor Ai Zheng 24: 924-9. (2005).	100
199. Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther 3: 611-7. (2005).	100
200. The phenothiazine drugs inhibit hERG potassium channels. Drug Chem Toxicol 28: 303-13. (2005).	100
201. Role of sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2 Cardiovasc Res 68: 441-53. (2005).	100
202. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmo Cardiovasc Res 67: 498-509. (2005).	100
203. Microfluidic gradient-generating device for pharmacological profiling. Anal Chem 77: 3897-903. (2005).	100
204. A novel splice mutation of HERG in a Chinese family with long QT syndrome. J Zhejiang Univ Sci B 6: 626-30. (2005).	100
205. Estimation of potency of HERG channel blockers: impact of voltage protocol and t J Pharmacol Toxicol Methods 52: 146-53. (0).	100
206. Automated electrophysiology in the preclinical evaluation of drugs for potential J Pharmacol Toxicol Methods 52: 123-35. (0).	100
207. Carvedilol's antiarrhythmic properties: therapeutic implications in patients wit Clin Cardiol 28: 165-73. (2005).	100
208. Molecular predictors of drug-induced prolongation of the QT interval. Curr Med Chem Cardiovasc Hematol Agents 3: 105-18. (2005).	100
209. The Potent Inhibitory Effects of Cisapride, a Specific Blocker for Human Ether-a Cancer Biol Ther 4: 295-301. (2005).	100
210. In silico modelling of ADMET-a minireview of work from 2000 to 2004. SAR QSAR Environ Res 16: 1-11. (0).	100
211. Modulating effect of ginseng saponins on heterologously expressed HERG currents Acta Pharmacol Sin 26: 551-8. (2005).	100
212. The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 10: 67-76. (2005).	100
213. Conservation and specialization in PAS domain dynamics. Protein Eng Des Sel 18: 127-37. (2005).	100
214. Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent Hum Exp Toxicol 24: 19-25. (2005).	100
215. Effect of change in posture and exercise on repolarization in patients with long Can J Cardiol 21: 33-8. (2005).	100
216. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ Res 15: 399-411. (0).	100
217. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590-7. (2005).	100.0
218. Molecular and clinical determinants of drug-induced long QT syndrome: an iatroge Swiss Med Wkly 134: 685-94. (2004).	100
219. QTc interval prolongation in patients on long-term methadone maintenance therapy Eur Addict Res 11: 44-9. (2005).	100
220. Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem Toxicol 27: 295-307. (2004).	100
221. Discovery of a small molecule activator of the human ether-a-go-go-related gene Mol Pharmacol 67: 827-36. (2005).	100.0
222. Targeting K+ channels for cancer therapy. J Exp Ther Oncol 4: 161-6. (2004).	100
223. QT prolongation through hERG K(+) channel blockade: current knowledge and strate Med Res Rev 25: 133-66. (2005).	100
224. Identification of a KCNE2 gain-of-function mutation in patients with familial at Am J Hum Genet 75: 899-905. (2004).	100.0
225. Physicochemical determinants for drug induced blockade of HERG potassium channel Curr Med Chem Cardiovasc Hematol Agents 1: 225-41. (2003).	100
226. IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents 1: 203-23. (2003).	100
227. Cardiac IKr channels minimally comprise hERG 1a and 1b subunits. J Biol Chem 279: 44690-4. (2004).	100.0
228. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ J Pharmacol Sci 95: 311-9. (2004).	100
229. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 66: 240-9. (2004).	100.0
230. [Long QT syndrome gene diagnosis by haplotype analysis] Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21: 272-3. (2004).	100
231. Four potassium channel mutations account for 73% of the genetic spectrum underly Ann Med 36: 53-63. (2004).	100.0
232. Functional interaction between extracellular sodium, potassium and inactivation J Physiol 558: 729-44. (2004).	100
233. Inactivation gating determines drug potency: a common mechanism for drug blockad Acta Pharmacol Sin 25: 554-60. (2004).	100
234. Long-term follow-up of notched T waves in female patients with LQT2 (HERG) mutat Jpn Heart J 45: 243-50. (2004).	100
235. A model for identifying HERG K+ channel blockers. Bioorg Med Chem 12: 2307-15. (2004).	100
236. Long QT syndrome in neonates: conduction disorders associated with HERG mutation J Am Coll Cardiol 43: 826-30. (2004).	100.0
237. Molecular and functional characterization of common polymorphisms in HERG (KCNH2 Am J Physiol Heart Circ Physiol 286: H2434-41. (2004).	100.0
238. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium Circulation 109: 26-9. (2004).	100.0
239. Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibito Biol Pharm Bull 26: 1661-7. (2003).	100
240. Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 6: 667-74. (2003).	100
241. [18-year old patient with anti-epileptic therapy and sudden cardiac death] Z Kardiol 92: 747-53. (2003).	100
242. HTS techniques to investigate the potential effects of compounds on cardiac ion Curr Opin Drug Discov Devel 6: 462-9. (2003).	100
243. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QT Expert Opin Drug Saf 1: 121-8. (2002).	100
244. Structural and functional basis for the long QT syndrome: relevance to veterinar J Vet Intern Med 17: 473-88. (0).	100
245. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch Pharmacol 368: 41-8. (2003).	100.0
246. Q-T peak dispersion in congenital long QT syndrome: possible marker of mutation Circ J 67: 495-8. (2003).	100
247. The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 139: 567-74. (2003).	100.0
248. QT interval prolongation and cardiac risk assessment for novel drugs. Curr Opin Investig Drugs 4: 303-8. (2003).	100
249. BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mech Biophys J 84: 3022-36. (2003).	100.0
250. Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 284: H256-67. (2003).	100.0
251. HERG potassium channels are constitutively expressed in primary human acute myel Leukemia 16: 1791-8. (2002).	100.0
252. Association between HERG K897T polymorphism and QT interval in middle-aged Finni J Am Coll Cardiol 40: 511-4. (2002).	100.0
253. [Ventricular arrhythmias. A potential risk associated with the use of non-cardio Minerva Med 93: 181-97. (2002).	100
254. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HE J Pharmacol Exp Ther 302: 320-7. (2002).	100.0
255. A virtual screening method for prediction of the HERG potassium channel liabilit Chembiochem 3: 455-9. (2002).	100
256. Long QT syndrome in children: the value of rate corrected QT interval and DNA an J Med Screen 8: 173-7. (2001).	100
257. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocyte Acta Pharmacol Sin 22: 125-31. (2001).	100
258. Development and evaluation of high throughput functional assay methods for HERG J Biomol Screen 6: 325-31. (2001).	100.0
259. [The effect of second generation histamine antagonists on the heart] Pneumonol Alergol Pol 69: 217-26. (2001).	100
260. [Testosterone modulation of HERG potassium channel blockade induced by neurolept Fiziol Zh 47: 11-8. (2001).	100
261. [T wave abnormalities on Holter monitoring of congenital long QT syndrome: pheno Arch Mal Coeur Vaiss 94: 470-8. (2001).	100
262. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassi J Pharmacol Exp Ther 297: 753-61. (2001).	100.0
263. Prolonged QT interval and sudden infant death--report of two cases. Forensic Sci Int 115: 147-53. (2001).	100
264. [Present concepts of congenital long QT syndrome] Arch Mal Coeur Vaiss 93: 17-21. (2000).	100
265. Novel gain-of-function mechanism in K(+) channel-related long-QT syndrome: alter Circ Res 86: 507-13. (2000).	100.0
266. HERG-Like potassium current regulates the resting membrane potential in glomus c J Neurophysiol 83: 1150-7. (2000).	100.0
267. [Molecular genetics of the long QT syndrome: clinical aspects] Orv Hetil 140: 2633-8. (1999).	100
268. Regulation of deactivation by an amino terminal domain in human ether-à-go-go-r J Gen Physiol 112: 637-47. (1998).	100.0
269. Inhibition of cardiac delayed rectifier K+ current by overexpression of the long Circ Res 83: 668-78. (1998).	100.0
270. [Molecular genetics of cardiovascular diseases] Rinsho Byori 46: 249-57. (1998).	100
271. Multi-undulant T-U-wave, sinus bradycardia and long QT syndrome: a possible phen Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 38: 267-75. (0).	100
272. [Congenital long QT syndromes] Arch Mal Coeur Vaiss 90: 25-35. (1997).	100
273. The molecular genetics of the congenital long QT syndromes. Curr Opin Cardiol 11: 45-51. (1996).	100
274. [Spasm of normal or irregular coronary arteries. Long-term outcome of 277 patien Arch Mal Coeur Vaiss 88: 1819-25. (1995).	100
275. [Comparison of the antispastic effect of Bi-Tildiem 120 mg and Tildiem 60mg] Ann Cardiol Angeiol (Paris) 44: 372-7. (1995).	100
276. [Vasospastic angina with angiographically normal coronary vessels of iatrogenic Ann Cardiol Angeiol (Paris) 41: 39-46. (1992).	100
277. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolo J Pharmacol Toxicol Methods 53: 1-10. (0).	100
278. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg Med Chem 0: . (2006).	100
279. Development and evaluation of an in silico model for HERG binding. J Chem Inf Model 46: 392-400. (0).	100
280. Isolated perfused and paced guinea pig heart to test for drug-induced changes of J Pharmacol Toxicol Methods 0: . (2006).	100
281. The long QT syndrome family of cardiac ion channelopathies: A HuGE review. Genet Med 8: 143-55. (2006).	100
282. Optimisation and validation of a medium-throughput electrophysiology-based hERG J Pharmacol Toxicol Methods 0: . (2006).	100
283. Determination of hERG channel blockers using a decision tree. Bioorg Med Chem 0: . (2006).	100
284. A QSAR model of HERG binding using a large, diverse, and internally consistent t Chem Biol Drug Des 67: 284-96. (2006).	100
285. Quantitative structure-activity relationship studies on inhibition of HERG potas J Chem Inf Model 46: 1371-8. (0).	100
286. [Electrophysiological characterization of long QT syndrome associated mutations Zhonghua Xin Xue Guan Bing Za Zhi 34: 523-7. (2006).	100
287. In Silico Classification of hERG Channel Blockers: a Knowledge-Based Strategy. ChemMedChem 1: 622-630. (2006).	100
288. An Accurate and Interpretable Bayesian Classification Model for Prediction of hE ChemMedChem 1: 315-322. (2006).	100
289. Orange flavonoid hesperetin modulates cardiac hERG potassium channel via binding Nutr Metab Cardiovasc Dis 0: . (2006).	100
290. [Effects of antimalarial drugs and cardiomyocytes. Pathogenic approach and new t Bull Acad Natl Med 190: 439-49; discuss. (2006).	100
291. Design, synthesis, structure-activity relationship, and in vivo activity of azab Bioorg Med Chem 0: . (2006).	100
292. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaD Xenobiotica 36: 877-901. (0).	100
293. Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gen J Appl Toxicol 0: . (2006).	100
294. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with redu J Pharmacol Toxicol Methods 54: 130-40. (0).	100
295. Are hERG channel inhibition and QT interval prolongation all there is in drug-in J Pharmacol Toxicol Methods 53: 87-105. (0).	100
296. [The long QT syndrome from the bedside to molecular genetic laboratory. The hist Orv Hetil 146: 2011-6. (2005).	100
297. Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbi J Pharmacol Toxicol Methods 52: 115-22. (0).	100
298. A Novel Approach Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) f Chem Res Toxicol 0: . (2007).	100
299. Assessing hERG Channel Inhibition Using PatchXpress. Clin Lab Med 27: 201-8. (2007).	100
300. Maprotiline block of the human ether-a-go-go-related gene (HERG) K+ channel. Arch Pharm Res 30: 453-60. (2007).	100
301. Suitability of commonly used excipients for electrophysiological in-vitro safety J Pharmacol Toxicol Methods 0: . (2007).	100
302. Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 trans Acta Pharmacol Sin 28: 959-67. (2007).	100
303. Estimation of hERG inhibition of drug candidates using multivariate property and Bioorg Med Chem 0: . (2007).	100
304. Action potential experiments complete hERG assay and QT-interval measurements in J Pharmacol Toxicol Methods 0: . (2007).	100
305. Expression and fuactional role of HERG1, K(+) channels in leukemic cells and leu J Huazhong Univ Sci Technolog Med Sci 27: 257-60. (2007).	100
306. Overexpression of hERG1 in resected esophageal squamous cell carcinomas: A marke J Surg Oncol 0: . (2007).	100
307. The 5-HT(4) Agonists Cisapride, Mosapride, and CJ-033466, a Novel Potent Compoun J Pharmacol Sci 0: . (2007).	100
308. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamic J Comput Chem 0: . (2007).	100
309. Expression and significance of HERG protein in gastric cancer. Cancer Biol Ther 7: . (2007).	100
310. A Composite Model for hERG Blockade. ChemMedChem 0: . (2007).	100
311. hERG Classification Model Based on a Combination of Support Vector Machine Metho Mol Pharm 0: . (2008).	100
312. [The mechanistic rote of KCNH2 gene L413P and L559H mutations in long QT syndrom Zhonghua Nei Ke Za Zhi 46: 838-41. (2007).	100
313. Modeling hERG and its Interactions with Drugs: Recent Advances in Light of Curre ChemMedChem 0: . (2008).	100
314. Prolong qt interval and "torsades de pointes" associated with different group of drugs. Georgian Med News 0: 45-9. (2007).	100
315. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 0: . (2008).	100
316. Identification of "toxicophoric" features for predicting drug-induced QT interval prolonga Eur J Med Chem 0: . (2008).	100
317. Computer-aided prediction of QT-prolongation. SAR QSAR Environ Res 19: 81-90. (2008).	100
318. HERG K(+) channel expression in CD34(+)/CD38 (-)/CD123 (high) cells and primary leukemia c Int J Hematol 0: . (2008).	100
319. Support vector machines classification of hERG liabilities based on atom types. Bioorg Med Chem 0: . (2008).	100
320. Shape Signatures: New Descriptors for Predicting Cardiotoxicity In Silico. Chem Res Toxicol 0: . (2008).	100
321. Identification of Novel Kv1.3 Blockers Using a Fluorescent Cell-Based Ion Channe J Biomol Screen 0: . (2005).	99
322. A Place for High-Throughput Electrophysiology in Cardiac Safety: Screening hERG J Biomol Screen 0: . (2005).	99
323. Evaluation of a high-throughput fluorescence assay method for HERG potassium cha J Biomol Screen 10: 339-47. (2005).	99
324. Identifying modulators of hERG channel activity using the PatchXpress planar pat J Biomol Screen 10: 168-81. (2005).	99
325. A novel membrane potential-sensitive fluorescent dye improves cell-based assays J Biomol Screen 7: 79-85. (2002).	99
326. Dynamic control of deactivation gating by a soluble amino-terminal domain in HER J Gen Physiol 115: 749-58. (2000).	99
327. Whole genome association study identifies polymorphisms associated with QT prolongation du Mol Psychiatry 0: . (2008).	99
328. The long QT syndrome: a clinical counterpart of hERG mutations. Novartis Found Symp 266: 186-98; discuss. (2005).	98
329. [Electropharmacological assessment of the risk of drug-induced long-QT syndrome Nippon Yakurigaku Zasshi 121: 384-92. (2003).	98
330. PROBING THE OUTER MOUTH STRUCTURE OF THE hERG CHANNEL WITH PEPTIDE TOXIN FOOTPRI Biophys J 0: . (2007).	98
331. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG ri J Pharmacol Toxicol Methods 52: 136-45. (0).	97
332. Extracellular sodium interacts with the HERG channel at an outer pore site. J Gen Physiol 120: 517-37. (2002).	97
333. Molecular mechanisms of arrhythmias. Rev Port Cardiol 17: II41-6. (1998).	97
334. Genomic organization and mutational analysis of HERG, a gene responsible for fam Hum Genet 102: 435-9. (1998).	97.0
335. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HER Naunyn Schmiedebergs Arch Pharmacol 359: 212-9. (1999).	96.6
336. Identification of the cyclic-nucleotide-binding domain as a conserved determinan J Cell Sci 118: 2803-12. (2005).	96
337. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potent Curr Med Chem 11: 2691-706. (2004).	96
338. Variability in the measurement of hERG potassium channel inhibition: effects of J Pharmacol Toxicol Methods 50: 93-101. (0).	96
339. ERG K+ channel blockade enhances firing and epinephrine secretion in rat chromaf FASEB J 17: 330-2. (2003).	96
340. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by t Nippon Yakurigaku Zasshi 119: 345-51. (2002).	96
341. Ion channels: structure of a molecular brake. Curr Biol 9: R173-5. (1999).	96
342. Erythromycin block of the HERG K(+) channel: Accessibility to F656 and Y652. Biochem Biophys Res Commun 341: 500-6. (2006).	96
343. Predictive models for HERG channel blockers: ligand-based and structure-based ap Curr Med Chem 14: 3003-26. (2007).	96
344. Homozygous premature truncation of the HERG protein : the human HERG knockout. Circulation 100: 1264-7. (1999).	95.7
345. Drug binding interactions in the inner cavity of hERG: Molecular insights from s Mol Pharmacol 0: . (2005).	95
346. Activation of HERG potassium channels by the diphenylurea NS1643. Mol Pharmacol 0: . (2005).	95
347. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression o Mol Pharmacol 68: 1254-70. (2005).	95
348. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers Mol Pharmacol 68: 876-84. (2005).	95
349. Intracellular K+ is required for the inactivation-induced high-affinity binding Mol Pharmacol 68: 855-65. (2005).	95
350. Activators of cation channels: potential in treatment of channelopathies. Mol Pharmacol 67: 585-8. (2005).	95
351. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol 66: 1093-102. (2004).	95
352. The molecular basis of long QT syndrome and prospects for therapy. Mol Med Today 4: 382-8. (1998).	95
353. Glycosylation of the osmoresponsive transient receptor potential channel TRPV4 o Am J Physiol Renal Physiol 0: . (2005).	95
354. Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol wi J Biol Chem 0: . (2006).	95
355. Short- and long-term effects of amiodarone on the two components of cardiac dela Circulation 103: 1317-24. (2001).	94.4
356. An ERG channel inhibitor from the scorpion Buthus eupeus. J Biol Chem 276: 9868-76. (2001).	94.4
357. Domperidone should not be considered a no-risk alternative to cisapride in the t Circulation 102: 1883-5. (2000).	94.4
358. Coupled K+-Water Flux through the HERG Potassium Channel Measured by an Osmotic J Gen Physiol 126: 529-38. (2005).	94
359. Molecular Determinants of hERG Channel Block. Mol Pharmacol 0: . (2006).	94
360. Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding Clin Chem 47: 1390-5. (2001).	93.3
361. Nuclear magnetic resonance structural studies of a potassium channel-charybdotox Biochemistry 44: 15834-41. (2005).	93
362. Specificity of TRH receptor coupling to G-proteins for regulation of ERG K+ chan J Physiol 566: 717-36. (2005).	93
363. Extracellular potassium effects are conserved within the rat erg K+ channel fami J Physiol 564: 329-45. (2005).	93
364. Clinical and electrophysiological characterization of a novel mutation R863X in J Mol Med 82: 189-96. (2004).	93
365. A comparison of currents carried by HERG, with and without coexpression of MiRP1 J Physiol 540: 15-27. (2002).	93
366. Functional characterization of the C-terminus of the human ether-à-go-go-relate J Physiol 534: 1-14. (2001).	93
367. State-dependent barium block of wild-type and inactivation-deficient HERG channe J Physiol 526: 265-78. (2000).	93
368. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel J Biol Chem 274: 27457-62. (1999).	93
369. Effects of phrixotoxins on the Kv4 family of potassium channels and implications Br J Pharmacol 126: 251-63. (1999).	93
370. Mutations of the S4-S5 linker alter activation properties of HERG potassium chan J Physiol 514: 667-75. (1999).	93
371. Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes. Am J Physiol 272: H1309-14. (1997).	93
372. HERG potassium channel activation is shifted by phorbol esters via protein kinas J Biol Chem 273: 25285-91. (1998).	92.9
373. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrh Ann N Y Acad Sci 868: 406-13. (1999).	92.3
374. Molecular genetics of long QT syndrome from genes to patients. Curr Opin Cardiol 12: 310-20. (1997).	92
375. A mutation in HERG associated with notched T waves in long QT syndrome. J Mol Cell Cardiol 28: 1609-15. (1996).	92
376. Potassium currents expressed from Drosophila and mouse eag cDNAs in Xenopus oocy Neuropharmacology 35: 841-50. (1996).	92
377. HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handb Exp Pharmacol 0: 349-55. (2006).	92
378. Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channe J Biol Chem 281: 4069-74. (2006).	92
379. Regulation of an ERG K+ current by Src tyrosine kinase. J Biol Chem 277: 13673-81. (2002).	91.7
380. Loratadine blockade of K(+) channels in human heart: comparison with terfenadine J Pharmacol Exp Ther 292: 261-4. (2000).	91.3
381. Direct block of hERG potassium channels by the protein kinase C inhibitor bisind Cardiovasc Res 64: 467-76. (2004).	91
382. Effects of the chromanol 293B, a selective blocker of the slow, component of the Cardiovasc Res 38: 441-50. (1998).	91
383. BcIV, a new paralyzing peptide obtained from the venom of the sea anemone Bunodo Biochim Biophys Acta 0: . (2006).	91
384. Do glia have heart? Expression and functional role for ether-a-go-go currents in J Neurosci 20: 3915-25. (2000).	90.9
385. Isolation and characterization of IKr in cardiac myocytes by Cs+ permeation. Am J Physiol Heart Circ Physiol 0: . (2005).	90
386. Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndr Br J Pharmacol 145: 3-4. (2005).	90
387. Suppression of electrical alternans by overexpression of HERG in canine ventricu Am J Physiol Heart Circ Physiol 286: H2342-51. (2004).	90
388. The long QT syndrome: new diagnostic and therapeutic approach in the era of mole Schweiz Med Wochenschr 126: 1727-31. (1996).	90
389. Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic d J Physiol 511: 3-14. (1998).	89.3
390. Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of J Biol Chem 279: 13289-92. (2004).	89
391. The antihistamine fexofenadine does not affect I(Kr) currents in a case report o Br J Pharmacol 137: 892-900. (2002).	89
392. Cloning and functional expression of rat ether-à-go-go-like K+ channel genes. J Physiol 513: 647-54. (1998).	89
393. Acceleration-induced action potential prolongation and early afterdepolarization J Cardiovasc Electrophysiol 9: 934-48. (1998).	89
394. A molecular basis for the therapy of the long QT syndrome. Arch Mal Coeur Vaiss 89: 1185-7. (1996).	89
395. HERG mutation predicts short QT based on channel kinetics but causes long QT by Cardiovasc Res 67: 467-75. (2005).	89
396. Notched T waves on Holter recordings enhance detection of patients with LQt2 (HE Circulation 103: 1095-101. (2001).	88.9
397. The Drosophila erg K+ channel polypeptide is encoded by the seizure locus. J Neurosci 17: 875-81. (1997).	88.9
398. Postnatal development of E-4031-sensitive potassium current in rat carotid chemo J Appl Physiol 98: 1469-77. (2005).	88
399. Amino terminal-dependent gating of the potassium channel rat eag is compensated J Physiol 502: 537-43. (1997).	88
400. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secr J Biol Chem 0: . (2006).	88
401. Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary a Br J Pharmacol 138: 161-71. (2003).	87.5
402. Molecular analysis of PIP2 regulation of HERG and IKr. Am J Physiol Heart Circ Physiol 287: H2154-63. (2004).	87
403. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ cha J Mol Cell Cardiol 36: 151-60. (2004).	87
404. The antiarrhythmic drug BRL-32872. Cardiovasc Drug Rev 20: 111-20. (2002).	87
405. Chemosensing at the carotid body. Involvement of a HERG-like potassium current i Adv Exp Med Biol 475: 241-8. (2000).	87
406. A single hERG mutation underlying a spectrum of acquired and congenital long QT J Mol Cell Cardiol 0: . (2007).	87
407. Recurrent intrauterine fetal loss due to near absence of HERG: Clinical and functional cha Heart Rhythm 5: 553-561. (2008).	87
408. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutati Circulation 99: 1464-70. (1999).	86.2
409. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blockin J Pharmacol Exp Ther 288: 1261-8. (1999).	86.2
410. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2: 758-72. (2005).	86
411. Exploring blocker binding to a homology model of the open hERG K+ channel using FEBS Lett 579: 2939-44. (2005).	86
412. Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) Basic Clin Pharmacol Toxicol 96: 123-30. (2005).	86
413. Regional specificity of human ether-a'-go-go-related gene channel activation and J Biol Chem 280: 7206-17. (2005).	86
414. Protein kinase A-mediated phosphorylation of HERG potassium channels in a human Chin Med J (Engl) 115: 668-76. (2002).	86
415. Long-term (subacute) potassium treatment in congenital HERG-related long QT synd J Cardiovasc Electrophysiol 10: 229-33. (1999).	86
416. The S4-S5 linker directly couples voltage sensor movement to the activation gate J Biol Chem 0: . (2006).	86
417. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical mo Br J Pharmacol 146: 792-9. (2005).	86
418. Activation gating of hERG potassium channels: S6 glycines are not required as ga J Biol Chem 0: . (2007).	86
419. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizo Br J Pharmacol 0: . (2007).	86
420. Interactions of the antimalarial drug mefloquine with the human cardiac potassiu J Pharmacol Exp Ther 299: 290-6. (2001).	85.7
421. Regulation of the human ether-a-gogo related gene (HERG) K+ channels by reactive Proc Natl Acad Sci U S A 94: 11698-703. (1997).	85.7
422. Two components of delayed rectifier K+ current in heart: molecular basis, functi Acta Pharmacol Sin 25: 137-45. (2004).	85
423. Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathi J Biol Chem 278: 42136-48. (2003).	85
424. Enhancement of HERG K(+) currents by Cd(2+) destabilization of the inactivated s Biophys J 77: 2534-41. (1999).	85
425. Block of HERG potassium channels by the antihistamine astemizole and its metabol J Cardiovasc Electrophysiol 10: 836-43. (1999).	85
426. Evaluation of the rubidium efflux assay for preclinical identification of HERG b Assay Drug Dev Technol 4: 73-82. (2006).	85
427. Co-chaperone FKBP38 promotes HERG trafficking. J Biol Chem 0: . (2007).	85
428. A tyrosine substitution in the cavity wall of a K channel induces an inverted in Biophys J 0: . (2008).	85
429. Modulation of HERG channel inactivation by external cations. J 33: 360-9. (2004).	84
430. Relevance of the proximal domain in the amino-terminus of HERG channels for regu FEBS Lett 535: 125-30. (2003).	84
431. Dual-function vector for protein expression in both mammalian cells and Xenopus Biotechniques 32: 536-8, 540. (2002).	84
432. A high-throughput HERG potassium channel function assay: an old assay with a new Drug Dev Ind Pharm 28: 177-91. (2002).	83.3
433. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agen Biochem Biophys Res Commun 280: 1243-50. (2001).	83.3
434. Rapid inactivation determines the rectification and [K+]o dependence of the rapi Circ Res 80: 782-9. (1997).	83.3
435. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing durin J Cardiovasc Electrophysiol 16: 537-45. (2005).	83
436. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administratio J Cardiovasc Electrophysiol 16: 329-41. (2005).	83
437. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) c J Cardiovasc Electrophysiol 15: 1302-9. (2004).	83
438. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K Naunyn Schmiedebergs Arch Pharmacol 370: 484-91. (2004).	83
439. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrom J Cardiovasc Electrophysiol 14: 1149-53. (2003).	83
440. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol 23: 58-77. (2003).	83
441. Gender differences in the long QT syndrome: effects of beta-adrenoceptor blockad Cardiovasc Res 53: 770-6. (2002).	83
442. The distinct HERG missense mutation L564P causes long QT syndrome in one French Can J Cardiol 16: 307-12. (2000).	83
443. Independent versus coupled inactivation in sodium channels. Role of the domain 2 J Gen Physiol 111: 451-62. (1998).	83
444. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration Heart Rhythm 2: 860-6. (2005).	83
445. Expression of human ERG K+ channels in the mouse heart exerts anti-arrhythmic ac Cardiovasc Res 65: 128-37. (2005).	82
446. Defective assembly and trafficking of mutant HERG channels with C-terminal trunc J Mol Cell Cardiol 37: 1225-33. (2004).	82
447. Activation of cardiac human ether-a-go-go related gene potassium currents is reg J Mol Med 82: 826-37. (2004).	82
448. Effects of gallium and mercury ions on transport systems. J Dent Res 80: 1753-7. (2001).	82
449. Interactions of a series of fluoroquinolone antibacterial drugs with the human c Mol Pharmacol 59: 122-6. (2001).	82
450. Application of cryopreserved cells to HERG screening using a non-radioactive Rb+ Assay Drug Dev Technol 4: 83-8. (2006).	82
451. Cardiovascular effects of KUR-1246, a new tetrahydronaphthalen derivative beta2- Arzneimittelforschung 56: 18-24. (2006).	82
452. Tuning out of hERG. Curr Opin Drug Discov Devel 11: 128-40. (2008).	82
453. Localization of the ergtoxin-1 receptors on the voltage sensing domain of hERG K(+) channe Pflugers Arch 0: . (2008).	82
454. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitr Br J Pharmacol 129: 1474-80. (2000).	81.8
455. Direct block of hERG potassium channels by caffeine. J Pharmacol Exp Ther 0: . (2005).	81
456. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig J Pharmacol Exp Ther 313: 888-95. (2005).	81
457. A model for recognition of polychlorinated dibenzo-p-dioxins by the aryl hydroca Eur J Biochem 269: 13-8. (2002).	81
458. The effect of external pH on the delayed rectifying K+ current in cardiac ventri Pflugers Arch 439: 739-51. (2000).	81
459. Effects of DM-9384, a cyclic derivative of GABA, on amnesia and decreases in GAB J Pharmacol Exp Ther 257: 271-5. (1991).	81
460. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone J Pharmacol Exp Ther 319: 1413-23. (2006).	81
461. [Erythromycin inhibits the proliferation of HERG K(+) channel highly expressing Zhonghua Yi Xue Za Zhi 86: 3353-7. (2006).	81
462. Neonatal Long QT Syndrome Due to a De Novo Dominant Negative hERG Mutation. Am J Crit Care 16: 416-412. (2007).	81
463. Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation 93: 1791-5. (1996).	80.4
464. Long QT Syndrome-Associated I593R Mutation in HERG Potassium Channel Activates E Cell Biochem Biophys 43: 365-78. (2005).	80
465. The low-potency, voltage-dependent HERG blocker propafenone--molecular determina Mol Pharmacol 66: 1201-12. (2004).	80
466. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 406: 341-3. (2000).	80
467. Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxa Drug Chem Toxicol 29: 303-12. (2006).	80
468. Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel Circ J 70: 502-8. (2006).	80
469. Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integ Mol Biol Cell 16: 2972-83. (2005).	80
470. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium 0: . (2007).	80
471. Homozygous deletion in KVLQT1 associated with Jervell and Lange-Nielsen syndrome Circulation 99: 1344-7. (1999).	79.3
472. Role of HERG-like K(+) currents in opossum esophageal circular smooth muscle. Am J Physiol 277: C1284-90. (1999).	79.2
473. T wave morphology analysis distinguishes between KvLQT1 and HERG mutations in lo Heart Rhythm 1: 285-92. (2004).	79
474. Molecular genetics of long-QT syndrome. Curr Opin Pediatr 10: 628-34. (1998).	79
475. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non J Pharmacol Toxicol Methods 54: 116-29. (0).	79
476. Interaction Simulation of hERG K(+) Channel with Its Specific BeKm-1 Peptide: In J Proteome Res 6: 611-20. (2007).	79
477. [HERG K+ channel, the target of anti-arrhythmias drugs] Yao Xue Xue Bao 42: 687-91. (2007).	79
478. Comparative evaluation of hERG potassium channel blockade by antipsychotics. Methods Find Exp Clin Pharmacol 29: 457-65. (2007).	79
479. Incorporation of the HERG Potassium Channel in a Mercury Supported Lipid Bilayer J Phys Chem B 0: . (2008).	79
480. Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carci Oncol Rep 19: 1511-6. (2008).	79
481. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EA Mol Pharmacol 60: 1343-8. (2001).	78.6
482. Gastrointestinal prokinetic drugs have different affinity for the human cardiac J Pharmacol Exp Ther 299: 1007-12. (2001).	78.6
483. Downregulation of the HERG (KCNH2) K+ channel by ceramide: evidence for ubiquiti J Cell Sci 118: 5325-34. (2005).	78
484. Novel indolylindazolylmaleimides as inhibitors of protein kinase C-beta: synthes J Med Chem 48: 1725-8. (2005).	78
485. Greater than the sum of its parts: combining models for useful ADMET prediction. J Med Chem 48: 1287-91. (2005).	78
486. Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor re J Med Chem 47: 6363-72. (2004).	78
487. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-pheny J Med Chem 47: 2318-25. (2004).	78
488. NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-s J Med Chem 47: 2089-96. (2004).	78
489. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibito J Med Chem 46: 2413-26. (2003).	78
490. Drug- and mutagenesis-induced changes in the selectivity filter of a cardiac two Cardiovasc Res 58: 46-54. (2003).	78
491. Identification, synthesis, and activity of novel blockers of the voltage-gated p J Med Chem 46: 486-98. (2003).	78
492. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a J Med Chem 45: 3844-53. (2002).	78
493. [Effects of sex hormones on HERG potassium channels expressed in Xenopus oocytes Fiziol Zh 47: 24-31. (2001).	78
494. I(Kr): the hERG channel. J Mol Cell Cardiol 33: 835-49. (2001).	78
495. Vulnerable substrate and multiple ion channel disorder in a diseased heart will Acta Pharmacol Sin 21: 289-95. (2000).	78
496. erg gene(s) expression during development of the nervous and muscular system of Mech Dev 95: 239-43. (2000).	78
497. Molecular mechanisms for drug interactions with hERG that cause long QT syndrome Expert Opin Drug Metab Toxicol 2: 81-94. (2006).	78
498. Insights for Human Ether-a-Go-Go-Related Gene Potassium Channel Inhibition Using J Med Chem 49: 5059-71. (2006).	78
499. Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 J Med Chem 49: 6569-84. (2006).	78
500. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) bloc J Med Chem 49: 6917-21. (2006).	78
501. Fluorescently Labeled Analogues of Dofetilide as High-Affinity Fluorescence Pola J Med Chem 0: . (2007).	78
502. Improved functional expression of recombinant human ether-a-go-go (hERG) K+ chan BMC Biotechnol 7: 93. (2007).	78
503. Discovery and Biological Evaluation of 5-Aryl-2-furfuramides, Potent and Selecti J Med Chem 0: . (2008).	78
504. Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol 130: 1967-75. (2000).	77.3
505. Comparison of HERG channel blocking effects of various beta-blockers - implicati Br J Pharmacol 0: . (2005).	77
506. Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 144: 840-8. (2005).	77
507. [Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsychotic agen Fiziol Zh 47: 17-25. (2001).	77
508. Altered gating of HERG potassium channels by cobalt and lanthanum. Pflugers Arch 440: 264-74. (2000).	77
509. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn J Pharmacol 83: 1-19. (2000).	77
510. Short QT syndrome. Cardiovasc Res 67: 357-66. (2005).	77
511. [Short QT Syndrome.] Herz 32: 206-10. (2007).	77
512. Exploring QSTR and toxicophore of hERG K(+) channel blockers using GFA and HypoG J Mol Graph Model 0: . (2007).	77
513. Coexistence of hERG current block and disruption of protein trafficking in ketoc Br J Pharmacol 0: . (2007).	77
514. A KCNE2 mutation in a patient with cardiac arrhythmia induced by auditory stimul Cardiovasc Res 0: . (2007).	77
515. Chlorthalidone inhibits the KvLQT1 potassium current in guinea-pig ventricular m Br J Pharmacol 0: . (2007).	77
516. Computational analysis of the effects of the hERG channel opener NS1643 in a human ventric Heart Rhythm 5: 734-41. (2008).	77
517. Improved Throughput of PatchXpress hERG Assay Using Intracellular Potassium Fluoride. Assay Drug Dev Technol 6: 235-41. (2008).	77
518. Tryptophan scanning mutagenesis of the HERG K+ channel: the S4 domain is loosely J Physiol 569: 367-79. (2005).	76
519. Mutations in the HERG K+-ion channel: a novel link between long QT syndrome and Am J Cardiol 95: 433-4. (2005).	76
520. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effect Br J Pharmacol 142: 1300-8. (2004).	76
521. Pharmacological rescue of trafficking defective HERG channels formed by coassemb Am J Physiol Heart Circ Physiol 287: H652-8. (2004).	76
522. Bidirectional ventricular tachycardia and channelopathy. Am J Cardiol 92: 991-5. (2003).	76
523. Inhibition of HERG potassium channels by cocaethylene: a metabolite of cocaine a Cardiovasc Res 53: 59-67. (2002).	76
524. Genotype and severity of long QT syndrome. Drug Metab Dispos 29: 574-9. (2001).	76
525. Biophysical properties and molecular basis of cardiac rapid and slow delayed rec Cell Physiol Biochem 9: 201-16. (1999).	76
526. A mitochondrial DNA mutation cosegregates with the pathophysiological U wave. Biochem Biophys Res Commun 257: 228-33. (1999).	76
527. Mechanisms and management of congenital and acquired long QT syndromes. Arch Mal Coeur Vaiss 89: 51-5. (1996).	76
528. Modulation of potassium channels as a therapeutic approach. Curr Pharm Des 12: 459-70. (2006).	76
529. Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Mala Br J Clin Pharmacol 61: 301-308. (2006).	76
530. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 12: 1431-48. (2006).	76
531. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells. J Pharmacol Toxicol Methods 0: . (2006).	76
532. Gating charges in the activation and inactivation processes of the HERG channel. J Gen Physiol 124: 703-18. (2004).	76
533. Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac Int J Toxicol 26: 25-31. (0).	76
534. Blockade of HERG K(+) channel by an antihistamine drug brompheniramine requires J Appl Toxicol 0: . (2007).	76
535. hERG Potassium Channels and the Structural Basis of Drug-Induced Arrhythmias. Chem Res Toxicol 0: . (2008).	76
536. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofet Clin Pharmacol Ther 77: 572-82. (2005).	75
537. Effects of oxypeucedanin on hKv1.5 and action potential duration. Biol Pharm Bull 28: 657-60. (2005).	75
538. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related G Basic Clin Pharmacol Toxicol 94: 209-12. (2004).	75
539. Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem 11: 1-11. (2004).	75
540. Local anaesthetic sensitivities of cloned HERG channels from human heart: compar Br J Anaesth 92: 93-101. (2004).	75.0
541. Dissociation of E-4031 from the HERG channel caused by mutations of an amino aci Cardiovasc Res 57: 651-9. (2003).	75
542. Molecular biology and cellular mechanisms of Brugada and long QT syndromes in in J Electrocardiol 34: 177-81. (2001).	75
543. Identical twins with long QT syndrome associated with a missense mutation in the Jpn Heart J 41: 399-404. (2000).	75
544. Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2. Cardiovasc Res 44: 283-93. (1999).	75
545. Characterization of an eag-like potassium channel in human neuroblastoma cells. J Physiol 508: 49-56. (1998).	75
546. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinit FEBS Lett 417: 28-32. (1997).	75
547. The human delta1261 mutation of the HERG potassium channel results in a truncate J Biol Chem 272: 705-8. (1997).	75.0
548. [Long QT syndrome] Nippon Rinsho 54: 776-81. (1996).	75
549. Na+ Permeation and Block of hERG Potassium Channels. J Gen Physiol 0: . (2006).	75
550. Early evaluation of compound QT prolongation effects: A predictive 384-well fluo J Pharmacol Toxicol Methods 0: . (2006).	75
551. New insights about HERG blockade obtained from protein modeling, potential energ Bioorg Med Chem 14: 3160-73. (2006).	75
552. Computer prediction of cardiovascular and hematological agents by statistical le Cardiovasc Hematol Agents Med Chem 5: 11-9. (2007).	75
553. Torsades de pointes complicating atrioventricular block: Evidence for a genetic Heart Rhythm 4: 170-4. (2007).	75
554. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic Heart Rhythm 4: 603-7. (2007).	75
555. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hER Epilepsy Res 63: 17-25. (2005).	74
556. Interaction between tetraethylammonium and permeant cations at the inactivation Jpn J Physiol 53: 25-34. (2003).	74
557. Ionic mechanisms underlying TRH-induced prolactin secretion in rat lactotrophs. Ross Fiziol Zh Im I M Sechenova 85: 195-204. (1999).	74
558. A role for inwardly rectifying K+ channels in differentiation of NG108-15 neurob J Neurobiol 38: 466-74. (1999).	74
559. N-linked glycosylation sites determine HERG channel surface membrane expression. J Physiol 515: 41-8. (1999).	74
560. Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization an Toxicol Pathol 34: 81-90. (2006).	74
561. Chemical modification of the human ether-a-go-go-related gene (HERG) k+ current Arch Pharm Res 29: 310-7. (2006).	74
562. Mutation Screening in KCNQ1, HERG, KCNE1, KCNE2 and SCN5A Genes in a Long QT Syn Ann Acad Med Singapore 36: 394-5. (2007).	74
563. Contributions of Herg K(+) current to repolarization of the human ventricular ac Prog Biophys Mol Biol 0: . (2007).	74
564. Augmentation of Late Sodium Current Unmasks the Proarrhythmic Effects of Amiodar Cardiovasc Res 0: . (2007).	74
565. [Effect of sophocarpine on HERG K+ channels] Yao Xue Xue Bao 43: 44-9. (2008).	74
566. HERG k(+) channel blockade by the novel antiviral drug sophocarpine. Biol Pharm Bull 31: 627-32. (2008).	74
567. The S4-S5 linker couples voltage sensing and activation of pacemaker channels. Proc Natl Acad Sci U S A 98: 11277-82. (2001).	73.3
568. Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3. Novartis Found Symp 266: 75-89; discussi. (2005).	73
569. Rb+ flux through hERG channels affects the potency of channel blocking drugs: co J Biomol Screen 9: 588-97. (2004).	73
570. Adrenergic regulation of the rapid component of the cardiac delayed rectifier po Basic Res Cardiol 99: 279-87. (2004).	73
571. Molecular basis of slow activation of the human ether-a-go-go related gene potas J Physiol 558: 417-31. (2004).	73
572. Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K( Life Sci 73: 429-35. (2003).	73
573. Regulation of the cardiac repolarizing HERG potassium channel by protein kinase Trends Cardiovasc Med 10: 205-9. (2000).	73
574. A novel role for HERG K+ channels: spike-frequency adaptation. J Physiol 501: 313-8. (1997).	73
575. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes l Am J Med Genet 65: 27-35. (1996).	73
576. Diabetes mellitus attenuates the repolarization reserve in mammalian heart. Cardiovasc Res 0: . (2006).	73
577. Preclinical cardiac safety assessment of pharmaceutical compounds using an integ Prog Biophys Mol Biol 90: 414-43. (0).	73
578. [Functional expression of congenital long QT syndrome related HERG mutation A561 Zhonghua Xin Xue Guan Bing Za Zhi 35: 143-6. (2007).	73
579. APETx1 from sea anemone Anthopleura elegantissima is a gating modifier peptide t Mol Pharmacol 0: . (2007).	73
580. K+ channels involved in contractility of rabbit small intestine. J Physiol Biochem 62: 227-36. (2006).	73
581. Protriptyline block of the human ether-à-go-go-related gene (HERG) K(+) channel Life Sci 0: . (2008).	73
582. Topological Mapping of the Asymmetric Drug Binding to the HERG Potassium Channel By Use of Mol Pharmacol 0: . (2008).	73
583. Survey of the coding region of the HERG gene in long QT syndrome reveals six nov Hum Mutat 15: 580-1. (2000).	72.7
584. A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes r J Physiol 509: 129-37. (1998).	72.7
585. CELL RENEWING IN NEUROBLASTOMA: ELECTROPHYSIOLOGICAL AND IMMUNOCYTOCHEMICAL CHAR Stem Cells 0: . (2005).	72
586. Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv Br J Pharmacol 146: 146-61. (2005).	72
587. A quantitative analysis of the activation and inactivation kinetics of HERG expr J Physiol 502: 45-60. (1997).	72
588. Soluble or bound laminin elicit in human neuroblastoma cells short- or long-term Cell Adhes Commun 4: 369-85. (1996).	72
589. A HERG-like K+ channel in rat F-11 DRG cell line: pharmacological identification J Physiol 496: 13-23. (1996).	72
590. Gastrointestinal Symptoms in Families of Patients with an SCN5A-Encoded Cardiac Am J Gastroenterol 101: 1299-304. (2006).	72
591. Dynamic conformational changes of extracellular S5-P linkers in the hERG channel J Physiol 569: 75-89. (2005).	72
592. Molecular Dynamics and Continuum Electrostatics Studies of Inactivation in the H J Phys Chem B Condens Matter Mater Surf Interfaces 111: 1090-1098. (2007).	72
593. Phosphatidylinositol 4,5-bisphosphate interactions with the HERG K(+) channel. Pflugers Arch 0: . (2007).	72
594. [3H]dofetilide binding to HERG transfected membranes: a potential high throughpu Eur J Pharmacol 430: 147-8. (2001).	71.4
595. Propranolol inhibits the human ether-a-go-go-related gene potassium channels. Eur J Pharmacol 519: 208-11. (2005).	71
596. Differential effects of human ether-a-go-go-related gene (HERG) blocking agents Eur J Pharmacol 512: 53-60. (2005).	71
597. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol 510: 75-85. (2005).	71
598. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockad J Pharmacol Toxicol Methods 50: 187-99. (0).	71
599. Absence of clinically important HERG channel blockade by three compounds that in Eur J Pharmacol 502: 163-7. (2004).	71
600. HERG channel (dys)function revealed by dynamic action potential clamp technique. Biophys J 88: 566-78. (2005).	71
601. Acquired QT interval prolongation and HERG: implications for drug discovery and Eur J Pharmacol 500: 129-42. (2004).	71
602. Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadin Eur J Pharmacol 497: 223-31. (2004).	71
603. Characterization of a KCNQ1/KVLQT1 polymorphism in Asian families with LQT2: imp J Mol Cell Cardiol 37: 79-89. (2004).	71
604. Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK29 Eur J Pharmacol 484: 41-8. (2004).	71
605. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol 482: 31-7. (2003).	71
606. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of Eur J Pharmacol 477: 69-72. (2003).	71
607. Ethanol differently affects stress protein and HERG K+ channel expression in SH- Eur J Pharmacol 459: 121-9. (2003).	71
608. The long QT syndrome: a novel missense mutation in the S6 region of the KVLQT1 g Hum Genet 100: 356-61. (1997).	71
609. Species Diversity and Peptide Toxins Blocking Selectivity of ERG Subfamily K+ Ch Mol Pharmacol 0: . (2006).	71
610. In-vitro experimental models for the risk assessment of antibiotic-induced QT pr Eur J Pharmacol 0: . (2006).	71
611. Modulation of HERG gating by a charge cluster in the N-terminal proximal domain. Biophys J 91: 4381-91. (2006).	71
612. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, an Eur J Pharmacol 532: 270-8. (2006).	71
613. Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potas Mol Pharmacol 52: 314-22. (1997).	70.6
614. Comparison of kinetic properties of quinidine and dofetilide block of HERG chann Eur J Pharmacol 493: 29-40. (2004).	70
615. Drugs, hERG and sudden death. Cell Calcium 35: 543-7. (2004).	70
616. Genetics, molecular mechanisms and management of long QT syndrome. Ann Med 30: 58-65. (1998).	70
617. QT PRODACT: Evaluation of the Potential of Compounds to Cause QT Interval Prolon J Pharmacol Sci 99: 449-57. (2005).	70
618. Biophysical characterization of the new HERG1 channel opener NS3623. Mol Pharmacol 0: . (2006).	70
619. Blockade by NIP-142, an Antiarrhythmic Agent, of Carbachol-Induced Atrial Action J Pharmacol Sci 0: . (2006).	70
620. Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evid J Physiol 0: . (2007).	70
621. Cardiac potassium channel dysfunction in sudden infant death syndrome. J Mol Cell Cardiol 0: . (2007).	70
622. Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedebergs Arch Pharmacol 365: 29-37. (2002).	69.2
623. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on FEBS Lett 512: 59-66. (2002).	69.2
624. Novel KCNQ1 and HERG missense mutations in Dutch long-QT families. Hum Mutat 13: 301-10. (1999).	69.2
625. Novel C-terminus frameshift mutation, 1122fs/147, of HERG in LQT2: additional am J Mol Cell Cardiol 37: 1205-11. (2004).	69
626. S641 contributes HERG k+ channel inactivation. Cell Biochem Biophys 41: 25-40. (2004).	69
627. Modulation of HERG potassium channel function by drug action. Ann Med 36: 41-6. (2004).	69
628. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhy J Physiol 551: 253-62. (2003).	69
629. [Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane] J Soc Biol 196: 339-48. (2002).	69
630. Effects of premature stimulation on HERG K(+) channels. J Physiol 537: 843-51. (2001).	69
631. Differential effects of amino-terminal distal and proximal domains in the regula Biophys J 79: 231-46. (2000).	69
632. A New Class of Blockers of the Voltage-Gated Potassium Channel Kv1.3 via Modific J Med Chem 49: 1433-41. (2006).	69
633. Solution structure of APETx2, a specific peptide inhibitor of ASIC3 proton-gated Protein Sci 14: 2003-10. (2005).	69
634. A splice site mutation in hERG leads to cryptic splicing in human long QT syndrome. J Mol Cell Cardiol 0: . (2008).	69
635. Autosomal recessive long-QT syndrome (Jervell Lange-Nielsen syndrome) is genetic Hum Genet 100: 573-6. (1997).	68.6
636. Single nucleotide polymorphism map of five long-QT genes. J Mol Med 83: 159-65. (2005).	68
637. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by c Br J Pharmacol 128: 444-50. (1999).	68
638. Modulation of human erg K+ channel gating by activation of a G protein-coupled r J Physiol 511: 333-46. (1998).	68
639. Recent advances in understanding the molecular mechanisms of the long QT syndrom J Cardiovasc Electrophysiol 6: 1023-31. (1995).	68
640. Food intake suppressant effect of baclofen in rats. Gen Pharmacol 20: 701-3. (1989).	68
641. Involvement of GABAA receptor sites in diazepam hypothermia. Gen Pharmacol 20: 855-9. (1989).	68
642. Effect of S5P {alpha}-helix charge mutants on inactivation of hERG K+ channels. J Physiol 0: . (2006).	68
643. Antimony-based antileishmanial compounds prolong the cardiac action potential by Mol Pharmacol 69: 1216-25. (2006).	68
644. Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 0: . (2007).	68
645. VEGFR-1 (FLT-1), {beta}1 integrin and hERG K+ channel form a macromolecular sign Blood 0: . (2007).	68
646. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97 FEBS Lett 414: 435-8. (1997).	67.6
647. HERG block, QT liability and sudden cardiac death. Novartis Found Symp 266: 118-31; discuss. (2005).	67
648. Predictive models for hERG potassium channel blockers. Bioorg Med Chem Lett 15: 3637-42. (2005).	67
649. A discriminant model constructed by the support vector machine method for HERG p Bioorg Med Chem Lett 15: 2886-90. (2005).	67
650. Discovery of potent and use-dependent sodium channel blockers for treatment of c Bioorg Med Chem Lett 15: 2943-7. (2005).	67
651. NMDA-NR2B subtype selectivity of stereoisomeric 2-(1,2,3,4-tetrahydro-1-isoquino Bioorg Med Chem Lett 15: 2231-4. (2005).	67
652. A two-state homology model of the hERG K+ channel: application to ligand binding Bioorg Med Chem Lett 15: 1737-41. (2005).	67
653. Discovery and structure-activity relationships of 2-benzylpyrrolidine-substitute Bioorg Med Chem Lett 15: 1225-8. (2005).	67
654. Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol 36: 701-5. (2004).	67
655. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic Bioorg Med Chem Lett 14: 2823-7. (2004).	67
656. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors Bioorg Med Chem Lett 14: 351-5. (2004).	67
657. Prediction of hERG potassium channel affinity by traditional and hologram qSAR m Bioorg Med Chem Lett 13: 2773-5. (2003).	67
658. Modulation of rat erg1, erg2, erg3 and HERG K+ currents by thyrotropin-releasing J Physiol 532: 143-63. (2001).	67
659. Droperidol lengthens cardiac repolarization due to block of the rapid component J Cardiovasc Electrophysiol 10: 1597-604. (1999).	67
660. Effects of TRH on heteromeric rat erg1a/1b K+ channels are dominated by the rerg J Physiol 0: . (2005).	67
661. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 0: . (2006).	67
662. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blocke Bioorg Med Chem Lett 0: . (2006).	67
663. Discovery and synthesis of tetrahydroindolone derived semicarbazones as selectiv Bioorg Med Chem Lett 0: . (2006).	67
664. Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of ph Bioorg Med Chem Lett 16: 1780-3. (2006).	67
665. 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) an Bioorg Med Chem Lett 16: 2008-12. (2006).	67
666. Synthesis of the first sulfur-35-labeled hERG radioligand. Bioorg Med Chem Lett 16: 1692-5. (2006).	67
667. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with mini Bioorg Med Chem Lett 0: . (2006).	67
668. PD-307243 Causes Instantaneous Current Through Human Ether-a-go-go-Related Gene Mol Pharmacol 0: . (2007).	67
669. Modulation of voltage-gated Na(+) and K(+) channels by pumiliotoxin 251D: A “joi Toxicon 0: . (2007).	67
670. Gambierol, a toxin produced by the dinoflagellate Gambierdiscus toxicus, is a potent block Toxicon 0: . (2008).	67
671. OdK2, a Kv1.3 channel-selective toxin from the venom of the Iranian scorpion Odonthobuthus Toxicon 0: . (2008).	67
672. Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol 43: 1625-9. (2004).	66.7
673. Compound mutations: a common cause of severe long-QT syndrome. Circulation 109: 1834-41. (2004).	66.7
674. The HERG K+ channel: progress in understanding the molecular basis of its unusua Eur Biophys J 33: 89-97. (2004).	66.7
675. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium ch Naunyn Schmiedebergs Arch Pharmacol 363: 472-80. (2001).	66.7
676. Multiple different missense mutations in the pore region of HERG in patients wit Hum Genet 102: 265-72. (1998).	66.7
677. The long QT syndrome. A review of recent molecular genetic and physiologic disco Medicine (Baltimore) 75: 1-5. (1996).	66.7
678. Drug-induced QT interval prolongation–regulatory guidance and perspectives on h Novartis Found Symp 266: 251-80; discuss. (2005).	66
679. In silico modelling–pharmacophores and hERG channel models. Novartis Found Symp 266: 171-81; discuss. (2005).	66
680. Physicochemical basis for binding and voltage-dependent block of hERG channels b Novartis Found Symp 266: 159-66; discuss. (2005).	66
681. Structural determinants for high-affinity block of hERG potassium channels. Novartis Found Symp 266: 136-50; discuss. (2005).	66
682. Voltage sensor movement in the hERG K+ channel. Novartis Found Symp 266: 46-52; discussi. (2005).	66
683. Acute effects of dronedarone on both components of the cardiac delayed rectifier Br J Pharmacol 140: 996-1002. (2003).	66
684. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) cu J Pharmacol Exp Ther 303: 688-94. (2002).	66
685. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein t Br J Pharmacol 149: 481-9. (2006).	66
686. In vivo Effects of Mutant HERG K(+) Channel Inhibition by Disopyramide in Patien J Cardiovasc Electrophysiol 0: . (2007).	66
687. Refining insights into high affinity drug binding to the hERG potassium channel (Relates t Mol Pharmacol 0: . (2008).	66
688. Human ether-à-go-go-related gene K+ channel gating probed with extracellular ca J Gen Physiol 113: 565-80. (1999).	65.4
689. HERG channel trafficking. Novartis Found Symp 266: 57-69; discussi. (2005).	65
690. The N588K-HERG K+ channel mutation in the ‘short QT syndrome’: mechanism of gain Biochem Biophys Res Commun 334: 441-9. (2005).	65
691. Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A recepto Naunyn Schmiedebergs Arch Pharmacol 370: 492-9. (2004).	65
692. The erg-like potassium current in rat lactotrophs. J Physiol 518: 401-16. (1999).	65
693. Inhibition of HERG channels stably expressed in a mammalian cell line by the ant Br J Pharmacol 127: 243-51. (1999).	65
694. Voltage-dependent blockade of HERG channels expressed in Xenopus oocytes by exte J Physiol 507: 631-8. (1998).	65
695. Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. FEBS Lett 417: 43-7. (1997).	65
696. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molec Antimicrob Agents Chemother 49: 4721-32. (2005).	64
697. Physical and functional interaction between integrins and hERG potassium channel Biochem Soc Trans 32: 826-7. (2004).	64
698. Temperature dependence of human Ether-a-go-go Related Gene (hERG) K+ currents. Am J Physiol Cell Physiol 0: . (2006).	64
699. Restoring depressed HERG K+ channel function as a mechanism for insulin treatmen Am J Physiol Heart Circ Physiol 0: . (2006).	64
700. Expression and Functional Characterization of the Human Ether-à-go-go-Related G J Membr Biol 0: . (2006).	64
701. Development, interpretation and temporal evaluation of a global QSAR of hERG ele J Comput Aided Mol Des 0: . (2007).	64
702. Understanding hERG inhibition with QSAR models based on a one-dimensional molecu J Comput Aided Mol Des 0: . (2007).	64
703. Genomic structure, transcriptional control and tissue distribution of human ERG1 Am J Physiol Heart Circ Physiol 0: . (2008).	64
704. Thermodynamical and kinetic properties of amino terminal and S4-S5 loop HERG cha Biophys J 0: . (2008).	64
705. Electrophysiological and Fluorescence Microscopy Studies with HERG Channel/EGFP Fusion Pro J Membr Biol 0: . (2008).	64
706. M-type KCNQ2-KCNQ3 potassium channels are modulated by the KCNE2 subunit. FEBS Lett 480: 137-41. (2000).	63.6
707. Gating and assembly of heteromeric hERG1a/1b channels underlying I(Kr) in the he Novartis Found Symp 266: 4-15; discussio. (2005).	63
708. Use of in vitro methods to predict QT prolongation. Toxicol Appl Pharmacol 207: 446-50. (2005).	63
709. Further insights into the effect of quinidine in short QT syndrome caused by a m J Cardiovasc Electrophysiol 16: 54-8. (2005).	63
710. Normal function of HERG K+ channels expressed in HEK293 cells requires basal pro FEBS Lett 534: 125-32. (2003).	63
711. Novel heterocyclic-substituted benzofuran histamine H(3) receptor antagonists: I Biochem Pharmacol 73: 1243-55. (2007).	63
712. Genetic control of heart function and aging in Drosophila. Trends Cardiovasc Med 17: 177-82. (2007).	63
713. Structural determinants and biophysical properties of HERG and KCNQ1 channel gat J Mol Cell Cardiol 35: 27-35. (2003).	62.5
714. Modulation of the K(+) channels encoded by the human ether-a-gogo-related gene-1 Mol Pharmacol 56: 1298-308. (1999).	62.5
715. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible eff Eur J Pharmacol 374: 457-60. (1999).	62
716. Mechanism of hERG K(+) channel blockade by the fluoroquinolone antibiotic moxifl Br J Pharmacol 0: . (2006).	62
717. Short QT syndrome: A case report and review of literature. Resuscitation 0: . (2006).	62
718. Different relevance of inactivation and F468 residue in the mechanisms of hEag1 FEBS Lett 580: 5059-66. (2006).	62
719. Modelling and imaging cardiac repolarization abnormalities. J Intern Med 259: 91-106. (2006).	62
720. Drug block of the hERG potassium channel: Insight from modeling. Proteins 0: . (2007).	62
721. Suppression of slow delayed rectifier current by a truncated isoform of KvLQT1 c J Biol Chem 272: 24109-12. (1997).	61.8
722. A novel extracellular calcium sensing mechanism in voltage-gated potassium ion c J Neurosci 21: 4143-53. (2001).	61.1
723. Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Mol Pharmacol 59: 1069-76. (2001).	61.1
724. Suppression of mammalian K+ channel family by ebastine. J Pharmacol Exp Ther 281: 233-44. (1997).	61.1
725. In vivo targeting of ERG potassium channels in mice and dogs by a positron-emitt Exp Mol Med 37: 269-75. (2005).	61
726. {Omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels. Am J Physiol Cell Physiol 289: C1251-60. (2005).	61
727. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channe Anesthesiology 103: 102-12. (2005).	61
728. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 370: 183-92. (2004).	61
729. Expression of voltage-gated K+ channels in human atrium. Basic Res Cardiol 97: 424-33. (2002).	61
730. A novel toxin from the venom of the scorpion Tityus trivittatus, is the first me FEBS Lett 0: . (2006).	61
731. Inhibition of cardiac hERG potassium channels by tetracyclic antidepressant mianserin. Naunyn Schmiedebergs Arch Pharmacol 0: . (2008).	61
732. Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol 38: 75-80. (2005).	60
733. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone Biochem Biophys Res Commun 325: 883-91. (2004).	60
734. Preclinical strategies to assess QT liability and torsadogenic potential of new J Electrocardiol 37: 7-14. (2004).	60
735. Selective expression of HERG and Kv2 channels influences proliferation of uterin Int J Oncol 25: 153-9. (2004).	60
736. Functional characterization of the common amino acid 897 polymorphism of the car Cardiovasc Res 59: 603-11. (2003).	60.0
737. Gating currents associated with intramembrane charge displacement in HERG potass Proc Natl Acad Sci U S A 100: 10534-9. (2003).	60.0
738. Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channe Eur J Pharmacol 458: 25-9. (2003).	60
739. Disopyramide is an effective inhibitor of mutant HERG K(+) channels involved in J Mol Cell Cardiol 0: . (2006).	60
740. Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sen Toxicology 0: . (2006).	60
741. Gene sequencing in neonates and infants with the long QT syndrome. Genet Test 9: 281-4. (2005).	60
742. Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implicat Naunyn Schmiedebergs Arch Pharmacol 371: 516-25. (2005).	59
743. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and h Bioorg Med Chem Lett 13: 1829-35. (2003).	59
744. Mapping the receptor site for ergtoxin, a specific blocker of ERG channels. FEBS Lett 510: 45-9. (2002).	59
745. Stereoselective interactions of the enantiomers of chromanol 293B with human vol J Pharmacol Exp Ther 294: 955-62. (2000).	59
746. Characterization of a novel missense mutation in the pore of HERG in a patient w J Cardiovasc Electrophysiol 10: 1262-70. (1999).	59
747. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor FEBS Lett 385: 77-80. (1996).	59
748. The Cardiac hERG/I(Kr) Potassium Channel as Pharmacological Target: Structure, F Curr Pharm Des 12: 2271-83. (2006).	59
749. hERG1 channels in human esophagus: Evidence for their aberrant expression in the J Cell Physiol 0: . (2006).	59
750. Mallotoxin is a Novel Human Ether-a-go-go-Related Gene (hERG) Potassium Channel J Pharmacol Exp Ther 0: . (2006).	59
751. Long QT 1 Mutation KCNQ1A344V Increases Local Anesthetic Sensitivity of the Slow Anesthesiology 105: 511-520. (2006).	59
752. Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine J Mol Neurosci 30: 17-8. (2006).	59
753. Comparative evaluation of HERG currents and QT intervals following challenge wit J Pharmacol Exp Ther 316: 1098-106. (2006).	59
754. Green tea flavonoid epigallocatechin-3-gallate (EGCG) inhibits cardiac hERG pota Biochem Biophys Res Commun 0: . (2007).	59
755. 5-HT(4) receptor agonists: similar but not the same. Neurogastroenterol Motil 20: 99-112. (2008).	59
756. Mechanism of action potential prolongation by RP 58866 and its active enantiomer Circulation 94: 2938-46. (1996).	58.1
757. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of J Cardiovasc Pharmacol 46: 7-17. (2005).	58
758. Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of a Naunyn Schmiedebergs Arch Pharmacol 370: 423-35. (2004).	58
759. Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpr J Cardiovasc Pharmacol 43: 706-14. (2004).	58
760. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of act Br J Pharmacol 123: 23-30. (1998).	58
761. Inhibition of the HERG K(+) channel by the antifungal drug ketoconazole depends FEBS Lett 0: . (2006).	58
762. Effects of Antipsychotic Drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT P Pharm Res 0: . (2006).	58
763. 1,4-Dihydroindeno[1,2-c]pyrazoles with Acetylenic Side Chains as Novel and Poten J Med Chem 0: . (2007).	58
764. Molecular Interaction of Droperidol with Human Ether-a-go-go-related Gene Channe Anesthesiology 106: 967-976. (2007).	58
765. Famotidine does not induce long QT syndrome: experimental evidence from in vitro Eur J Pharmacol 466: 137-46. (2003).	57.1
766. Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine m Br J Pharmacol 131: 1081-8. (2000).	57
767. Molecular biology of the long QT syndrome: impact on management. Pacing Clin Electrophysiol 20: 2052-7. (1997).	57
768. Involvement of Golgin-160 in Cell Surface Transport of Renal ROMK Channel: Co-ex Cell Physiol Biochem 17: 1-12. (2006).	57
769. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromy J Pharmacol Exp Ther 318: 352-9. (2006).	57
770. Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the Pflugers Arch 0: . (2008).	57
771. Clinical, genetic, and electrophysiologic characteristics of a new PAS-domain HE Ann Noninvasive Electrocardiol 10: 334-41. (2005).	56
772. Variable expression of long QT syndrome among gene carriers from families with f Ann Noninvasive Electrocardiol 7: 40-6. (2002).	56
773. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimoz Eur J Pharmacol 392: 137-40. (2000).	56
774. Functional Significance of KCNH2 (HERG) K897T Polymorphism for Cardiac Repolariz Ann Noninvasive Electrocardiol 11: 57-62. (2006).	56
775. A missense mutation (G604S) in the S5/pore region of HERG causes long QT syndrom Eur J Pediatr 0: . (2006).	56
776. Template switching within exons 3 and 4 of KV11.1 (HERG) gives rise to a 5′ trun Biochem Biophys Res Commun 345: 1342-9. (2006).	56
777. Overexpression HERG K(+) channel gene mediates cell-growth signals on activation J Cell Physiol 0: . (2007).	56
778. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum Mutat 20: 382-91. (2002).	55.6
779. Posttranslational modulation of glucocorticoid feedback inhibition at the pituit Endocrinology 143: 3796-801. (2002).	55.6
780. Inhibition of human ether-a-go-go potassium channels by cocaine. Mol Pharmacol 59: 269-77. (2001).	55.6
781. HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibrone J Biol Chem 276: 4923-31. (2001).	55.6
782. Sulfonylureas blockade of neural and cardiac HERG channels. FEBS Lett 440: 125-30. (1998).	55.2
783. Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac J Pharmacol Exp Ther 296: 573-83. (2001).	55
784. Molecular determinants of cocaine block of human ether-á-go-go-related gene pot J Pharmacol Exp Ther 317: 865-74. (2006).	55
785. Pharmacological activation of IKr current suppresses bradycardia-induced trigger J Pharmacol Exp Ther 0: . (2007).	55
786. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 Anesth Analg 106: 1161-70, table . (2008).	55
787. Mechanism for the effects of extracellular acidification on HERG-channel functio Am J Physiol 277: H1283-92. (1999).	54.2
788. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium ch Br J Pharmacol 120: 968-74. (1997).	54
789. Molecular dissection of venom from Chinese scorpion Mesobuthus martensii: Identi Peptides 0: . (2006).	54
790. Frequency-dependent modulation of KCNQ1 and HERG1 potassium channels. Biochem Biophys Res Commun 0: . (2006).	54
791. Combined hERG channel inhibition and disruption of trafficking in drug-induced l Br J Pharmacol 0: . (2006).	54
792. Cardiac Glycosides as Novel Inhibitors of HERG Channel Trafficking. J Pharmacol Exp Ther 0: . (2006).	54
793. An integrated in silico 3D model-driven discovery of a novel, potent, and select J Med Chem 49: 3116-35. (2006).	54
794. A novel structure-based virtual screening model for the hERG channel blockers. Biochem Biophys Res Commun 0: . (2007).	54
795. The eag family of K+ channels in Drosophila and mammals. Ann N Y Acad Sci 868: 356-69. (1999).	53.8
796. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF se Br J Cancer 93: 781-92. (2005).	53
797. Inactivation block of the HERG human cardiac K+ channels by RP58866. Br J Pharmacol 127: 1899-907. (1999).	53
798. HERG- and IRK-like inward rectifier currents are sequentially expressed during n Eur J Neurosci 9: 2596-604. (1997).	53
799. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarizatio Br J Pharmacol 0: . (2005).	53
800. Olanzapine prolongs cardiac repolarization by blocking the rapid component of th J Psychopharmacol 0: . (2006).	53
801. The effects of sevoflurane and propofol on QT interval and heterologously expres Anesth Analg 102: 98-103. (2006).	53
802. Identification and Characterization of 4-Methylbenzyl 4-[(Pyrimidin-2-ylamino)me J Med Chem 0: . (2007).	53
803. Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongat Clin Pharmacol Ther 0: . (2007).	53
804. Sigma-2 receptor ligands-mediated inhibition of inwardly rectifying K+ channels J Pharmacol Exp Ther 0: . (2007).	53
805. Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol 0: . (2004).	52
806. HERG K channel conductance promotes H2O2-induced apoptosis in HEK293 cells: cell Cell Physiol Biochem 14: 121-34. (2004).	52
807. Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereo Br J Pharmacol 137: 1269-79. (2002).	52
808. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ chan Eur J Pharmacol 412: 203-12. (2001).	52
809. RERG is a molecular correlate of the inward-rectifying K current in clonal rat p Receptors Channels 6: 19-29. (1998).	52
810. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarizatio Br J Pharmacol 0: . (2005).	52
811. Molecular characterization of two founder mutations causing long QT syndrome and Ann Med 38: 294-304. (2006).	52
812. A novel hypothesis for the binding mode of HERG channel blockers. Biochem Biophys Res Commun 344: 72-8. (2006).	52
813. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel. Bioorg Med Chem Lett 0: . (2007).	52
814. Inhibition of the rapid component of the delayed rectifier potassium current in ventricula Br J Pharmacol 0: . (2008).	52
815. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 74: 31-6. (2005).	51
816. Probucol aggravates long QT syndrome associated with a novel missense mutation M Clin Sci (Lond) 107: 175-82. (2004).	51
817. Blockade of HERG human K(+) channels and I(Kr) of guinea-pig cardiomyocytes by t Br J Pharmacol 0: . (2006).	51
818. Doxazosin induces apoptosis of cells expressing hERG K(+) channels. Eur J Pharmacol 0: . (2007).	51
819. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr Med Chem Cardiovasc Hematol Agents 1: 273-87. (2003).	50.0
820. Inhibition of cardiac HERG potassium channels by the atypical antidepressant tra Naunyn Schmiedebergs Arch Pharmacol 370: 146-56. (2004).	50
821. Characterization of the inhibitory effects of erythromycin and clarithromycin on Mol Cell Biochem 254: 1-7. (2003).	50.0
822. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG ch Cardiovasc Res 57: 660-9. (2003).	50.0
823. Effects of irbesartan on cloned potassium channels involved in human cardiac rep J Pharmacol Exp Ther 304: 862-73. (2003).	50.0
824. Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol 137: 221-8. (2002).	50.0
825. Nicotine depresses the functions of multiple cardiac potassium channels. Life Sci 65: PL143-9. (1999).	50
826. Long-term exposure to retinoic acid induces the expression of IRK1 channels in H Biochem Biophys Res Commun 244: 706-11. (1998).	50
827. hERG K(+) channel blockade by the antipsychotic drug thioridazine: An obligatory Biochem Biophys Res Commun 0: . (2006).	50
828. Cooperative Interactions Between R531 and Acidic Residues in the Voltage Sensing Cell Physiol Biochem 21: 37-46. (2008).	50
829. Does hERG coassemble with a beta subunit? Evidence for roles of MinK and MiRP1. Novartis Found Symp 266: 100-12; discuss. (2005).	49
830. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and Am J Ther 12: 328-36. (0).	49
831. Molecular physiology of cardiac delayed rectifier K+ channels. Heart Vessels 0: 170-2. (1997).	49
832. Expression of ether à go-go potassium channels in human gliomas. Neurosci Lett 368: 249-53. (2004).	48
833. Erg K+ channels modulate contractile activity in the bovine epididymal duct. Am J Physiol Regul Integr Comp Physiol 0: . (2008).	48
834. Expression and role of hERG channels in cancer cells. Novartis Found Symp 266: 225-32; discuss. (2005).	47
835. Effects of estradiol on cardiac ion channel currents. Eur J Pharmacol 0: . (2006).	47
836. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35: 1060-3. (2007).	47
837. In-vitro experimental models for the risk assessment of antibiotic-induced QT pr Eur J Pharmacol 577: 222-32. (2007).	47
838. Long-QT syndrome-associated missense mutations in the pore helix of the HERG pot Circulation 104: 1071-5. (2001).	46.7
839. HERG K(+) currents in human prolactin-secreting adenoma cells. Pflugers Arch 445: 589-600. (2003).	46
840. Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y huma Biochem Pharmacol 62: 1229-38. (2001).	46
841. Blockade of HERG channels expressed in Xenopus oocytes by external H+. Pflugers Arch 438: 23-9. (1999).	46
842. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG Naunyn Schmiedebergs Arch Pharmacol 0: . (2006).	46
843. C101, a novel 4-amino-piperidine derivative selectively blocks N-type calcium channels. Eur J Pharmacol 0: . (2008).	46
844. Homozygosity for a HERG potassium channel mutation causes a severe form of long J Am Coll Cardiol 35: 1919-25. (2000).	45.5
845. Genetic approaches to cardiovascular disease. Supravalvular aortic stenosis, Wil Circulation 92: 142-7. (1995).	45.5
846. Heart rate variability in patients with congenital long QT syndrome. Ann Noninvasive Electrocardiol 6: 298-304. (2001).	45
847. A novel K+ channel blocker isolated from ‘hiccup nut’ toxin. Neuroreport 7: 2575-9. (1996).	45
848. Interactions Between Charged Residues in the Transmembrane Segments of the Volta J Membr Biol 207: 169-81. (2005).	45
849. Atypical tetracyclic antidepressant maprotiline is an antagonist at cardiac hERG Naunyn Schmiedebergs Arch Pharmacol 373: 212-20. (2006).	45
850. Acute administration of alcohol modulates pyroglutamyl amino peptidase II activi Neurochem Int 46: 347-56. (2005).	45
851. Hydrogen peroxide modifies the kinetics of HERG channel expressed in a mammalian J Pharmacol Exp Ther 297: 96-102. (2001).	44.4
852. Inhibition of cardiac delayed rectifier K+ currents by an antisense oligodeoxynu Pflugers Arch 442: 329-35. (2001).	44
853. Inhibition of IKs in guinea pig cardiac myocytes and guinea pig IsK channels by Pflugers Arch 432: 1094-6. (1996).	44
854. The functional HERG variant 897T is associated with Conn’s adenoma. J Hypertens 24: 479-487. (2006).	44
855. Electrophysiological effects of brompheniramine on cardiac ion channels and acti Pharmacol Res 0: . (2006).	44
856. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K(+ Eur J Pharmacol 0: . (2006).	44
857. Sphingolipid metabolite ceramide causes metabolic perturbation contributing to H Cell Physiol Biochem 20: 429-40. (2007).	44
858. Phospholipid Lysophosphatidylcholine as a Metabolic Trigger and HERG as an Ionic Cell Physiol Biochem 20: 417-28. (2007).	44
859. Biophysical properties of heteromultimeric erg K+ channels. Pflugers Arch 445: 423-30. (2002).	43
860. Blockade of HERG human K(+) channel and I(Kr) of guinea pig cardiomyocytes by pr Eur J Pharmacol 0: . (2006).	43
861. Inhibitory effect of carboxylic acid group on hERG binding. Bioorg Med Chem Lett 16: 5507-12. (2006).	43
862. Risperidone prolongs cardiac repolarization by blocking the rapid component of t J Cardiovasc Pharmacol 41: 934-7. (2003).	42.9
863. Saxitoxin is a gating modifier of HERG K+ channels. J Gen Physiol 121: 583-98. (2003).	42.9
864. Effects of different types of K+ channel modulators on the spontaneous myogenic Acta Physiol Scand 173: 323-33. (2001).	42.9
865. Phospholipid metabolite 1-palmitoyl-lysophosphatidylcholine enhances human ether Circulation 104: 2645-8. (2001).	42.9
866. Changes in the mRNA levels of delayed rectifier potassium channels in human atri Cardiology 92: 248-55. (1999).	42.3
867. Demonstration of an inwardly rectifying K+ current component modulated by thyrot Pflugers Arch 435: 119-29. (1997).	42
868. Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block at Naunyn Schmiedebergs Arch Pharmacol 0: . (2007).	42
869. The hERG K(+) channel: target and antitarget strategies in drug development. Pharmacol Res 0: . (2008).	42
870. Use-dependent ‘agonist’ effect of azimilide on the HERG channel. J Pharmacol Exp Ther 291: 1324-36. (1999).	41.7
871. Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxa Bioorg Med Chem Lett 0: . (2005).	41
872. Ureas with histamine H3-antagonist receptor activity–a new scaffold discovered Bioorg Med Chem Lett 16: 5303-8. (2006).	41
873. Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagoni Bioorg Med Chem Lett 16: 4262-5. (2006).	41
874. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable di Bioorg Med Chem Lett 0: . (2007).	41
875. Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac typ J Cardiovasc Pharmacol 42: 161-8. (2003).	40.0
876. Influence of amino-terminal structures on kinetic transitions between several cl J Membr Biol 187: 117-33. (2002).	40
877. Human ether-a-gogo related gene (HERG) K+ channels as pharmacological targets: p Biochem Pharmacol 55: 1741-6. (1998).	40
878. Comparative effects of loratadine and terfenadine on cardiac K+ channels. J Cardiovasc Pharmacol 30: 42-54. (1997).	40
879. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline. Eur J Pharmacol 0: . (2006).	40
880. Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethy Bioorg Med Chem Lett 0: . (2007).	40
881. Proton and zinc effects on HERG currents. Biophys J 77: 282-98. (1999).	39.1
882. ALTERING EXTRACELLULAR POTASSIUM CONCENTRATION DOES NOT MODULATE DRUG BLOCK OF H Clin Exp Pharmacol Physiol 33: 1059-65. (2006).	39
883. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for Int J Impot Res 18: 477-83. (0).	39
884. Discovery of novel and orally active NR2B-selective N-methyl-d-aspartate (NMDA) Bioorg Med Chem Lett 0: . (2007).	39
885. Effects of duramycin on cardiac voltage-gated ion channels. Naunyn Schmiedebergs Arch Pharmacol 0: . (2008).	39
886. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhyth Cardiovasc Res 50: 386-98. (2001).	38.9
887. Dofetilide block involves interactions with open and inactivated states of HERG Pflugers Arch 443: 520-31. (2002).	38.5
888. Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed Cell Physiol Biochem 9: 81-9. (1999).	38.5
889. Modulation of HERG potassium channel properties by external pH. Pflugers Arch 438: 419-22. (1999).	38
890. Asymmetrical distribution of ion channels in canine and human left-ventricular w Pflugers Arch 450: 307-16. (2005).	37
891. HERG potassium channels are more frequently expressed in human endometrial cance Br J Cancer 83: 1722-9. (2000).	37
892. Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol 0: . (2007).	37
893. Current concepts in long QT syndrome. Pediatr Cardiol 21: 542-50. (0).	36.7
894. Block of hERG channel by ziprasidone: Biophysical properties and molecular deter Biochem Pharmacol 0: . (2005).	36
895. Flunarizine is a Highly Potent Inhibitor of Cardiac hERG Potassium Current. J Cardiovasc Pharmacol 47: 211-20. (2006).	36
896. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5 Bioorg Med Chem Lett 16: 4311-5. (2006).	35
897. Functional consequences of methionine oxidation of hERG potassium channels. Biochem Pharmacol 0: . (2007).	35
898. HERG1 Currents in Native K562 Leukemic Cells. J Membr Biol 0: . (2007).	35
899. The membrane permeable calcium chelator BAPTA-AM directly blocks human ether a-g Biochem Pharmacol 0: . (2007).	35
900. Modulation of HERG current and herg gene expression during retinoic acid treatme J Neurobiol 40: 214-25. (1999).	34.8
901. Effects of Na+ channel blocker, pilsicainide, on HERG current expressed in HEK-2 J Cardiovasc Pharmacol 42: 410-8. (2003).	34
902. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adr Naunyn Schmiedebergs Arch Pharmacol 369: 462-72. (2004).	33.3
903. Single-channel recordings of a rapid delayed rectifier current in adult mouse ve J Physiol 556: 401-13. (2004).	33.3
904. Embryonic arrhythmia by inhibition of HERG channels: a common hypoxia-related te Epilepsia 43: 457-68. (2002).	33.3
905. Long-term modulation of HERG channel gating in hypoxia. Biochem Biophys Res Commun 286: 857-62. (2001).	33.3
906. The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) c Biochem Biophys Res Commun 286: 499-504. (2001).	33.3
907. Direct effects of candesartan and eprosartan on human cloned potassium channels Mol Pharmacol 59: 825-36. (2001).	33.3
908. Bradycardia-induced long QT syndrome caused by a de novo missense mutation in th Am J Med Genet 98: 348-52. (2001).	33.3
909. Additive Effects of Combined Application of Multiple hERG Blockers. J Cardiovasc Pharmacol 0: . (2008).	33
910. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence J Cardiovasc Pharmacol 47: 21-9. (2006).	32
911. Characterization of S818L mutation in HERG C-terminus in LQT2. Modification of a FEBS Lett 481: 197-203. (2000).	31.8
912. Cloned human inward rectifier K+ channel as a target for class III methanesulfon Circ Res 77: 1151-5. (1995).	31.4
913. Blockade of HERG channels expressed in Xenopus laevis oocytes by external divale Biophys J 76: 1959-71. (1999).	30.8
914. Compound heterozygosity for mutations Asp611-->Tyr in KCNQ1 and Asp609-->Gly in Clin Sci (Lond) 108: 143-50. (2005).	30
915. Open channel block by KCB-328 [1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4 J Pharmacol Exp Ther 302: 314-9. (2002).	30.0
916. Role of glycosylation in cell surface expression and stability of HERG potassium Am J Physiol Heart Circ Physiol 283: H77-84. (2002).	30.0
917. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 29: 182-9. (1999).	29
918. Inhibition of HERG channels by the local anaesthetic articaine. Eur J Anaesthesiol 0: 1-6. (2006).	29
919. Spinal circuits formation: a study of developmentally regulated markers in organ Neuroscience 122: 391-405. (2003).	28.6
920. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345 J Cardiovasc Electrophysiol 14: 651-8. (2003).	28.6
921. Expression and function of KCNH2 (HERG) in the human jejunum. Am J Physiol Gastrointest Liver Physiol 284: G883-95. (2003).	28.6
922. Clinical, genetic, and biophysical characterization of a homozygous HERG mutatio Pediatr Res 53: 744-8. (2003).	28.6
923. An amino acid residue whose change by mutation affects drug binding to the HERG FEBS Lett 506: 191-5. (2001).	28.6
924. Block of HERG current expressed in HEK293 cells by the Na+-channel blocker ciben Heart Vessels 19: 137-43. (2004).	28
925. Idiosyncratic gating of HERG-like K+ channels in microglia. J Gen Physiol 111: 795-805. (1998).	27.3
926. Functional analysis of a mouse brain Elk-type K+ channel. J Neurosci 19: 2906-18. (1999).	26.9
927. Ultrafast inactivation causes inward rectification in a voltage-gated K(+) chann J Neurosci 20: 511-20. (2000).	26.1
928. Inactivation gating determines nicotine blockade of human HERG channels. Am J Physiol 277: H1081-8. (1999).	26.1
929. The Effect of High Extracellular Potassium on IKr Inhibition by Anti-Arrhythmic Cardiology 108: 18-27. (2006).	26
930. QT interval prolongation: and the beat goes on. Mini Rev Med Chem 5: 1083-91. (2005).	26
931. Characterization of potassium channel modulators with QPatch automated patch-cla Assay Drug Dev Technol 1: 685-93. (2003).	25.0
932. The utility of hERG and repolarization assays in evaluating delayed cardiac repo J Cardiovasc Pharmacol 43: 369-79. (2004).	25.0
933. Differential effect of HERG blocking agents on cardiac electrical alternans in t Eur J Pharmacol 486: 209-21. (2004).	25.0
934. Potential mechanisms for the enhancement of HERG K+ channel function by phosphol Br J Pharmacol 141: 586-99. (2004).	25.0
935. Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308: 935-40. (2004).	25.0
936. BmTx3, a scorpion toxin with two putative functional faces separately active on Biochem J 378: 745-52. (2004).	25.0
937. Differential recovery of action potential duration and HERG currents from the ef J Cardiovasc Pharmacol 42: 648-55. (2003).	25.0
938. A radiolabeled peptide ligand of the hERG channel, [125I]-BeKm-1. Pflugers Arch 447: 55-63. (2003).	25.0
939. A HERG current sustains a cardiac-type action potential in neuroblastoma S cells Biochem Biophys Res Commun 302: 101-8. (2003).	25.0
940. Genetic variation affecting heart rate in Drosophila melanogaster. Genet Res 74: 121-8. (1999).	25.0
941. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin Exp Allergy 29: 174-81. (1999).	25
942. Histidines 578 and 587 in the S5-S6 linker of the human Ether-a-gogo Related Gen J Biol Chem 277: 8912-9. (2002).	23.1
943. Effects of outer mouth mutations on hERG channel function: a comparison with sim Biophys J 76: 3128-40. (1999).	23.1
944. Analysis of the human KCNH2(HERG) gene: identification and characterization of a Hum Mutat 15: 483. (2000).	22.7
945. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channe Eur J Pharmacol 457: 19-27. (2002).	22.2
946. Fenamate-induced enhancement of heterologously expressed HERG currents in Xenopu Eur J Pharmacol 452: 269-77. (2002).	22.2
947. Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type c J Pharm Pharmacol 53: 1671-8. (2001).	22
948. The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine bl Cardiovasc Res 55: 799-805. (2002).	20.0
949. Effects of external acidosis on HERG current expressed in Xenopus oocytes. J Mol Cell Cardiol 32: 11-21. (2000).	17.4
950. Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG Cardiovasc Res 54: 67-76. (2002).	16.7
951. Molecular cloning and expression of cERG, the ether à go-go-related gene from c Pflugers Arch 442: 188-91. (2001).	16.7
952. Functionally-distinct proton-binding in HERG suggests the presence of two bindin Cell Biochem Biophys 39: 183-93. (2003).	14.3
953. Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular act J Physiol 549: 667-72. (2003).	14.3
954. Modulation of human ether-à-go-go-related K+ (HERG) channel inactivation by Cs+ J Physiol 548: 691-702. (2003).	14.3
955. Redox state dependency of HERGS631C channel pharmacology: relation to C-type ina FEBS Lett 474: 111-5. (2000).	13.6
956. Long QT syndrome with a high mortality rate caused by a novel G572R missense mut Clin Genet 57: 125-30. (2000).	13.0
957. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55: 147-57. (0).	10.0
958. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syn Pediatr Cardiol 25: 459-65. (0).	3.3